

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018070
Article Type:	Research
Date Submitted by the Author:	06-Jun-2017
Complete List of Authors:	Huang, Chengzhi; Guangdong General Hospital, Department of General Hospital; Shantou University, Medical College Yu, Mengya; Guangdong General Hospital, Department of General Hospital; Southern Medical University Yao, Xueqing; Guangdong General Hospital; Shantou University, Medical College
<b>Primary Subject Heading</b>:	Genetics and genomics
Secondary Subject Heading:	Gastroenterology and hepatology, Oncology, Pathology, Surgery
Keywords:	microRNA-17, Cancer, Outcome, Prognosis, Meta-analysis

SCHOLARONE™  
Manuscripts

1  
2  
3 MicroRNA-17 and the prognosis of human carcinomas: a systematic review and  
4 meta-analysis

5  
6 Cheng-zhi Huang<sup>1,2</sup>, Meng-ya Yu<sup>1,3</sup>, Xue-qing Yao<sup>1,2#</sup>

7  
8 1 Department of General Surgery, Guangdong General Hospital (Guangdong Academy  
9 of Medical Science), Guangzhou, Guangdong, China.

10  
11 2 Medical College, Shantou University, Shantou, Guangdong, China.

12  
13 3 Southern Medical University, Guangzhou, Guangdong, China.

14  
15 # To whom correspondence should be addressed:

16  
17 Xue-qing Yao

18  
19 No.106 Zhongshan Road, Guangzhou, Guangdong, China, 510000.

20  
21 Phone: 020-83827812

22  
23 Fax: 020-83827812

24  
25 Email: [yjb9211@21cn.com](mailto:yjb9211@21cn.com)

26  
27  
28 **Abstract**

29  
30 **Objectives** MicroRNA-17 (miR-17) family has been thoroughly studied and reported to  
31 contribute to the progress of human carcinomas. However, the prognostic value of  
32 miR-17 in cancers remains unclear. Therefore, we put up with a systemic review and  
33 meta-analysis to summarize and analyze the relationship between the miR-17 status and  
34 clinical outcome in several kinds of human cancers.

35  
36  
37  
38 **Design** Published articles associated with miR-17 and clinical outcome of cancers were  
39 screened by searching the 7 online databases. The patients' survival results were pooled,  
40 and pooled hazard ratio (HR) with 95% confidential intervals (95% CI) were calculated  
41 and used for measuring the strength of association between miR-17 and the prognosis of  
42 cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell  
43 lymphoblastic lymphoma and colon cancer. Heterogeneity, publication bias and subgroup  
44 analysis were also conducted.

45  
46  
47  
48  
49  
50 **Results** In all 12 articles, totally 1096 patients were included in this meta-analysis. The  
51 results indicated that the increased expression of miR-17 played an unfavorable role in  
52 overall survival (OS) in various human carcinomas with the HR of 1.342 (95%  
53 CI=1.238-1.456) concerning the publication bias. In subgroup analysis, HR of ethnicity  
54  
55  
56  
57  
58  
59  
60

(Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and non-digestive system HR=1.54), detection method (qRT-PCR HR=1.40 and in situ hybridization, ISH HR=2.59) and detection sample (tissue HR=1.45 and serum HR=1.32), all  $p < 0.05$ . On the analysis of disease-free survival (DFS) and recurrence-free survival (RFS), the unfavorable prognosis role was also found with the increased expression of miR-17 (HR=1.40, 95% CI=1.23-1.60).

**Conclusions** miR-17 might be a useful biomarker in predicting the clinical outcome of human cancers.

**The article was registered in PROSPERO (No. CRD42017065749).**

**Keywords** microRNA-17; Cancer; Outcome; Prognosis; Meta-analysis.

### **Strength and limitation of this study**

1. This is the first meta-analysis that summarized and reported the microRNA-17 as a novel cancer prognosis biomarker in medical filed
2. We used board search strategy in order to minimize any potential publication bias.
3. We conducted the subgroup analysis and we found out that the up-regulated expression of microRNA-17 may implies poor clinical outcome in digestive system cancers.
4. The major limitation of our research is our meta-analysis included limited studies in western countries, which may decrease the applicability of our result among various ethnicities.

### **Introduction**

Despite great progresses have been made in the medical filed over the past few decades, cancer is still a key health burden problem all over the world. It has become the leading cause of death in worldwide. In the year 2017, it is estimated that 1,688,780 patients would be diagnosed with cancers, and 600,920 cancer deaths may occur in United States <sup>1</sup>. Since the implantations of the advanced methods of screening and adjuvant systemic therapies for newly diagnosed cases, the mortality rate of the cancers are declining in the developed countries <sup>2</sup>, whereas the clinical outcome of human cancers in the developing countries are still poor <sup>3 4</sup>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Nowadays, there are several independent factors that identifying and evaluating the clinical outcome of human cancers, including tumor size, histological grade, age of the patients and metastasis of lymph node<sup>5-8</sup>. Tumor biomarkers based on the tissue and serum are widely used to predict the prognosis of neoplasm. However, those techniques are far from satisfactory owing to the low specificity and sensitivity<sup>9-11</sup>. Thus, a more less invasive and accurate biomarker is of great value and in need for predicting the prognosis of human tumors.

The discovery of microRNAs (miRNAs) provided an innovative method for the prognosis of cancers by a less-invasive detection<sup>12</sup>. miRNAs, a class of endogenous non-coding single-stranded RNAs with the length of 18-25nt nucleotide, act as regulators of gene expression regulators via pairing with the complementary section in the 3'-untranslated region (3'-UTR) of its target mRNAs. MicroRNAs may act as a regulator in the metabolism process of cell growth, proliferation, differentiation and apoptosis<sup>13</sup>. As a tumor suppressors or oncogenes, microRNA potentially acts as a prognostic biomarker. Clinical studies have found that some miRNAs are differentially expressed between tumor and non-tumor tissues, and the abnormal expression of tumor-associated miRNAs can be detected in patient's blood, cancerous tissue and fecal samples<sup>14 15</sup>. Such as the microRNAs, miR-21, miR-203, and miR-206 are discovered aberrantly expressed in cancer patients<sup>16-18</sup>. Recent studies have demonstrated that aberrantly expressed miRNAs in kinds of cancers, especially those acting as suppressor or oncogene, are proved to be related to cancer development, progression and especially carcinogenic treatment<sup>19-21</sup>. Therefore, these miRNAs could be considered as useful prognostic biomarkers of various human cancers.

The miR-17 family, including six members, miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1, is one of the most thoroughly studied miRNA cluster with the critical role in the development of tumor<sup>22</sup>. These microRNAs are tightly located within an 800 base-pair region of human chromosome 13, play an essential role in the development of the heart, lung and human immune system<sup>23</sup>. Of the miR-17 family, recent studies are found that miR-17, functioning as a tumor suppressor, may act as an significant tumor indicator<sup>24 25</sup>. It is much more complicated in the development of cancer, and the increased expression of miR-17 may help to promote carcinogenesis and cancer

1  
2  
3 progression<sup>26-28</sup>. According miRBase (<http://www.mirbase.org>), miR-17 includes two  
4 members, miR-17-5p and miR-17-3p. Of the miR-17-3p and the miR-17-5p are located in  
5 the sequence of miR-17, with the structure of stem-loop. As a result, the detection of  
6 miR-17-5p, miR-17-3p has the same effect and result of detecting miR-17<sup>29-33</sup>.  
7  
8  
9

10 After the systematic review of published documents and journals, we assumed that  
11 the higher expression of the miR-17 indicates poor prognosis of the cancer patients<sup>34-45</sup>.  
12 However, we must admit that different confounding factors, including race, detection  
13 method, tumor location, may cause inconsistent and different results. Generally, though  
14 the aberrantly expression of miR-17 may imply the clinical outcome of cancer patients,  
15 but the relationship is not consistent. Thus, we conducted a full-scale meta-analysis to  
16 further evaluate the clinical availability of miR-17 as novel prognosis indicator for cancer  
17 detection.  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **Material and Methods**

### 27 **Data Source and Search Strategy**

28 All the relevant were searched articles in the following online electronic databases:  
29 PubMed, Web of Science, Embase, China Biomedical Literature Database (CBM),  
30 Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP),  
31 and Wan Fang databases up to May 15th, 2017. The year of publication and publishing  
32 status is without any restriction.  
33  
34  
35  
36  
37

38 Keywords for searching included: (1) prognosis OR prognostic OR survival OR  
39 outcome OR mortality; (2) cancer OR tumor OR tumour OR carcinoma OR neoplasm; (3)  
40 miR-17 OR microRNA-17 OR hsa-mir-17. Additionally, we also searched the references  
41 in the included researches and relevant published articles via Google Scholar.  
42  
43  
44  
45

### 46 **Inclusion and Exclusion Criteria**

47 The inclusion criteria of the articles are: (1) The cancers was diagnosed by the  
48 histological examination or any other committed standard; (2) studied miR-17 in human  
49 cancers; (3) the expression of miR-17 and the clinical outcome of patients was included  
50 in the research; and (4) reports with survival outcome and the data was further explored  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 considering hazard ratio (HR) with 95% confidence interval (95% CI) and HR with a  
4 *P*-value.  
5

6 The exclusion criteria are: (1) duplicate publications; (2) articles focus on other  
7 genes or other kind of cancer; (3) case report, reviews, letter, animals trail; (4)  
8 unqualified or insufficient data; (5) HR, 95% CI and *P*-value are not provided or cannot  
9 not be calculated and (6) articles concentrate on the polymorphisms or methylation  
10 patterns of a miRNA.  
11  
12  
13  
14

15 Any questions of suitability of the included articles was examined was discussed by  
16 the authors after the reviewing abstract and full text manuscript. The final decision was  
17 made by the academic committee.  
18  
19  
20  
21

## 22 **Data extraction and quality assessment**

23 All studies were decided by the two investigators (Huang and Yu) independently  
24 based on titles and abstracts. After the screening the studies, the full-text would require if  
25 the articles were potentially suitable for the research. Moreover, the literature search was  
26 performed again in the excluded articles by the investigators to avoid missing any  
27 potentially related to the study. We would turn to the original authors of the article if any  
28 supplementary data might be needed. Any disagreement was resolved by the two  
29 researchers. The extracted details of the articles are as follows: (1) publication  
30 information: the name of the authors, publication area, and publication year; (2) patient's  
31 characteristics: diseases, stage of the disease, RNA detection method, type of tissue  
32 sample and follow-up years; (3) the measurement of miR-17 measurement and it's cut-off  
33 value and (4) HR of miR-17 for overall survival (OS), disease-free survival (DFS) and  
34 recurrence-free survival (RFS), as well as their 95% CI and *P*-value. The HRs and their  
35 95% were extracted from the original articles or the E-mails from the author. If not, we  
36 calculated HR and 95% CI using the data of observed deaths, cancer recurrences or the  
37 original data provided by the authors. All calculation mentioned above were based on the  
38 methods provided by Parmar, M. K. et al.<sup>46</sup>. The quality of the included articles were  
39 systematically assessed based on a systematic review checklist of the Dutch Cochrane  
40 Centre proposed by MOOSE<sup>47</sup>.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Statistical analysis

The test of heterogeneity of pooled HRs was carried out by using Cochran's Q-test and Higgins  $I^2$  statistic. A  $P$ -value of  $< 0.05$  or  $I^2 > 50\%$  was considered as statistical significance. If the heterogeneity exists, the random effects model was performed among the included studies; otherwise, the fixed effects model was selected.  $I^2$  value ranges from 0% to 100%. All the  $P$ -values were two-sided.

HR  $> 1$  presents the up-regulated expression of miR-17 indicated poor prognosis in patients, and HR  $< 1$  suggested a better prognosis. Publication bias was evaluated by the Begg's test and Egger's test<sup>48 49</sup>. If the publication bias did exist, the Duval and the Tweedie's trim and fill method was used to adjust the results<sup>50</sup>. The STATA software Version 14.0 (StataCorp LP, College Station, TX, USA) was used in all of the statistical analyses.

## Results

### Literature selection

In total, 405 articles associated with miR-17 and cancer prognosis was identified from online database search. After removing the replicate records, 304 articles were left. 210 citations were removed from the analysis after the first screening base on the species, article type, and language. Then the remaining 104 studied were carefully reviewed and assessed the abstract and the full text. After that, 89 articles were excluded from the study because they were unrelated to miR-17 expression levels or because of lack of survival statistics such as HRs, 95% CI, or  $P$ -value. Finally, 15 studies, which investigated the potential relationship between miR-17 expression and prognosis of human digestive system cancers, remained for further detailed screening and data-extraction. Three of the study explains the relationship between miR-17 expression and the clinic outcome of cancer but the author did not provide the exact HR value, or the value cannot be calculated from the data. Thus, 12 articles (12 studies)<sup>34-45</sup> were included in this meta-analysis. (Figure 1)

### Clinical characteristics and data of selected studies



1  
2  
3 After reviewing the articles, 12 studies published between 2010 and 2016 were  
4 considered for the meta-analysis. All of the published study included in the study were  
5 the retrospective study<sup>34-45</sup>. Of the 12 studies, all of them reported patient's OS, and three  
6 studies also focus on the DFS or RFS. The type of the cancers included gastrointestinal  
7 cancers (colorectal cancer, gastric cancer), lung cancer, pancreatic cancer, hepatocellular  
8 cancer, osteosarcoma, human glioma, T-cell lymphoblastic lymphoma and esophageal  
9 squamous cell carcinoma. A total of 1096 patients from People's Republic of China,  
10 Japan, Spain and Brazil were diagnosed with various types of cancers. Quantitative  
11 real-time polymerase chain reaction (qRT-PCR) was used to assess the expression of  
12 miR-17 in 12 studies, one of study used the in-situ hybridization (ISH). All of the authors  
13 used the tissue and serum samples as the source of the miR-17. The majority (10 of 12) of  
14 the HRs were reported in the present analysis, all of which were calculated in  
15 multivariate analysis. The rest HRs could be estimated by analyzing Kaplan-Meier  
16 analysis and relative risk (RR) value. Most of the studies have the follow-up research for  
17 at least 38 months. The clinical characteristics of the studies included in this article are  
18 summarized in the Table 1.

### 31 32 **Association between miR-17 and overall survival (OS)**

33 Due to low heterogeneity ( $I^2=38.2\%$ ,  $P$ -value=0.086), fixed effects model was used  
34 to calculate and analyze the pooled HR value (HR=1.42, 95% CI=1.30-1.55), suggesting  
35 that the higher expression level of miR-17 significance implied the poor OS in patients  
36 with diverse kinds of cancers. Details of the meta-analysis are systematically summarized  
37 in the Figure 2.

38 In order to demonstrate the predictive role of miR-17, subgroups analysis was  
39 conducted based on the patient ethnicity, cancer type, the methods identifying  
40 microRNAs and type of tissue sample. Association was found in the Asian patients (HR  
41 1.40, 95% CI=1.27-1.55, fixed effects model) and Caucasian patients (HR 1.48, 95%  
42 CI=1.21-1.81, random effects model). In addition, the association was also significant in  
43 other subgroups, including digestive system cancers (HR 1.36, 95% CI=1.22-1.51, fixed  
44 effects model) and non-digestive system cancers (HR 1.54, 95% CI=1.33-1.78, fixed  
45 effects model), qRT-PCR detection method (HR 1.40, 95% CI=1.28-1.53, fixed effects  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 model) and ISH (HR 2.59, 95% CI=1.39-4.81), tissue sample (HR 1.45, 95%  
4 CI=1.31-1.61, fixed effects model) and serum sample (HR 1.32, 95% CI=1.10-1.57, fixed  
5 effects model). Details of the subgroup analysis are listed in the Table 2 and Figure 3.  
6  
7  
8  
9

### 10 **Correlation between miR-17 and disease-free survival (DFS) and recurrence-free** 11 **survival (RFS)**

12  
13 A total of 3 studies<sup>38 39 43</sup> are included in the analysis of DFS or RFS, revealing a  
14 predicative role of increased expression of miR-17 and the prognosis of the cancer  
15 patients (pooled HR= 1.40, 95% CI=1.23-1.60,  $p < 0.001$ ), which is determined by a  
16 fix-effect model ( $I^2=15.8\%$ ,  $P\text{-value}=0.305$ ) (Figure 4).  
17  
18  
19  
20  
21

### 22 **Publication bias**

23  
24 We used Begg's funnel plot and Egger's test to access the possible publication bias of  
25 the included researches<sup>48 49</sup>. In the analysis of relationship between miR-17 and the OS,  
26 the  $P$ -values of Egger's test and Begg's test were 0.014 and 0.011, respectively. Both of  
27 the Begg's test and Egger's test implies the publication bias, thus trim and fill method  
28 was performed to make pooled HR more reliable<sup>50</sup>. The adjusted HR was 1.342, 95%  
29 CI=1.238-1.456. The funnel plot and Egger's plot is demonstrated in the Figure 5.  
30  
31  
32  
33  
34  
35

### 36 **Discussion**

37  
38 Previous studies have showed that miRNAs appear to own a special expression  
39 profile in cancerous tissues, and they can be precisely detected by qRT-PCR in frozen,  
40 formalin-fixed, paraffin-embedded tissues and serum samples. Recently, miRNAs,  
41 serving as tumor suppressive or oncogenic genes, have been proved to play important  
42 roles in tumor genesis and progression of cancer, which are closely associated with many  
43 pathways such as cell cycle, angiogenesis, innate and adaptive immune responses,  
44 invasion, and metastasis.<sup>12 19</sup> Simultaneously, lots of studies have revealed the presence  
45 of miRNAs. And the potential use of microRNAs us a tumor biomarker in detecting  
46 tumor occurrence, development, and prognosis are reported in numerous researches.  
47 Unfortunately, effective diagnosis techniques and prognosis indicator of cancer have not  
48 been found. Considering the small survival chance of terminal stage of cancer,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

discovering a novel less-invasive detection method with higher accuracy in prognosis in cancer prognosis is of great significance in evaluating the patient's survival status.

Over the decades, there are increasing studies that made great contribution to uncover the acquaintance of miRNAs as biomarkers and the pathogenesis of cancer, as miRNAs could be obtained from the serum, urine, fecal samples without or less invasive procedure. The miR-17, a popular-studied microRNA, is found aberrantly expressed in different kinds of cancer, such as glioma<sup>51</sup>, esophageal or oral squamous cell carcinoma<sup>37 52</sup>, pancreatic cancer<sup>36</sup>, gastrointestinal cancers<sup>40</sup>, osteosarcoma<sup>53</sup> and Burkitt lymphoma<sup>39</sup>, and are significantly related to the clinic outcome of cancers. Researches are also found the detection of microRNA is even more accuracy than traditional cancer biomarkers in predicting the clinical outcomes of the human colon cancers<sup>54</sup>. However, there is still lack of adequate evidences that allow miRNAs as cancer biomarkers in clinical practice.

Our meta-analysis indicated that the elevated miR-17 expression is significantly associated with poor OS (HR=1.42) in patients with various types of carcinoma. Due to the publication bias implied by the Begg's test and the Egger's test, thus trim and fill method was performed to make pooled HR more reliable. The adjusted HR was 1.342. In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the Caucasian and Asian group, the digestive and non-digestive system group, the qRT-PCR and ISH detection method group, the tissue and serum sample group. Furthermore, in the analysis of DFS and RFS, we found that the increasing expression of miR-17 indicated the poor DFS and RFS in HCC and gastrointestinal cancers.

Yang et al. found that the miRNA-17 is overexpressed in the HCC tissue, and promotes the phosphorylation of heat shock protein 27 (HSP27). As a consequence, phosphorylated HSP27 enhanced the migration of the HCC cells, implying a significant simulative role of miRNA-17 in the progression of HCC<sup>55</sup>. Wang et al. found that the up-regulated expression of miRNA-17-5p promote cancer cells proliferation and inhibit apoptosis by post-transcript modulation of mRNA p21 and tumor protein p53-induced nuclear protein 1 (TP53INP1)<sup>56</sup>. Ma et al. reported that the overexpressed of miRNA-17 promote cancer cells progression by targeting gene P130<sup>57</sup>. Yan et al. reported that the over-expressed of the miR-17-5p is detected in the tissue of pancreatic cancer. The miR-17-5p inhibitor promotes the expression of Bim protein by targeting its

1  
2  
3 3'-untranslated region and negatively regulates at the posttranscriptional level. Therefore,  
4 the authors suggested that the miR-17-5p inhibitor may be novel therapeutic approach for  
5 pancreatic cancer.<sup>58</sup> Combined with our meta-analysis, these findings suggest that the  
6 detection of tissue or serum miR-17 expression may be a useful prognosis biomarker in  
7 the patients with HCC, pancreatic cancer, and gastrointestinal cancers.  
8  
9

10  
11  
12 There are various of limitations to consider. First, the power of the pooled HRs was  
13 not sufficient strong as the researches included in this study mainly focus on Asian  
14 people, lacking adequate concern on Caucasian or African population. Second, the  
15 statistical significance of the association result of miR-17 with various kinds of cancer  
16 was reduced with a relatively limited sample size of 1031 patients, as well as all of the  
17 studies are retrospective studies. As a result, further validations and clinical trials are  
18 crucially needed. Third, the lack of global consensus of miR-17 expression level makes it  
19 difficult to define a standard cut-off value. The definition of cut-off value varies as the  
20 studies. Some choose median value to define the expression level of miR-17, but some  
21 prefer the mean value. Therefore, the pooled outcome may be different from the actual  
22 value, causing the bias in the result of the effectiveness of miR-17 as a cancer prognostic  
23 biomarker. Forth, no heterogeneity was found in the meta-analysis except for the  
24 sub-group of Caucasian. The reason of heterogeneity may likely due to the different  
25 cancer type, races, and microRNAs detection method. Robaina et al.<sup>39</sup> reported higher  
26 prognostic value of miR-17 in Burkitt lymphoma by using ISH method in detecting  
27 miRNAs. For instance, when we stratified the OS studies according to the detection  
28 method, the lower heterogeneity was found in the qRT-PCR group ( $I^2=28.0$ ,  $P=0.086$ ).  
29 Fifth, the publication bias was found in the meta-analysis. The quality of the researches,  
30 the sample size, and the actual effectiveness of miR-17 as a tumor biomarker are the  
31 reasons of the publication bias.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Conclusions**

49  
50 In summary, our research suggested that miR-17 is a potential biomarker in various  
51 types of cancers. Moreover, under the limitation of our present study, more clinical  
52 studies with larger sample size, multi-center and prospective studies should be carried out  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 before miR-17 could be applied to a prognostic biomarker in the routine clinical guidance  
4 of cancers.  
5  
6  
7

## 8 **Funding**

9  
10 This work was supported and funded by the Guangdong Science and Technology  
11 Department (No. 2014A020212636).  
12  
13  
14

## 15 **Disclosure of conflicts**

16 The authors report no conflicts of interest in this work.  
17  
18  
19

## 20 **Ethics approval**

21 The article does not contain any studies with human participants or animals  
22 performed by any of the authors.  
23  
24  
25  
26  
27

## 28 **Contributors**

29 All authors conceived the study. Chengzhi Huang and Mengya Yu performed the  
30 search and reviewed the studeis. Chengzhi Huang performed the quality of evidence  
31 assessment. Chengzhi Huang and Mengya Yu performed the risk of bias assessment. The  
32 data were extracted and checked by Chengzhi Huang and Xueqing Yao, respectively.  
33 Chengzhi Huang and Xueqing Yao performed the statistical analysis. The manuscript was  
34 drafted by Chengzhi Huang and reviewed and amended by all authors. Xueqing Yao is  
35 guarantor.  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Data sharing statement**

45 No additional data are available.  
46  
47  
48

## 49 **Reference**

- 50  
51  
52 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*  
53 2017;67(1):7-30. doi: 10.3322/caac.21387  
54  
55 2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J*  
56  
57  
58  
59

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Clin* 2015;65(2):87-108. doi: 10.3322/caac.21262
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66(2):115-32. doi: 10.3322/caac.21338
  4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012;62(4):220-41. doi: 10.3322/caac.21149
  5. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. *Cancer* 1969;24(5):1071-80.
  6. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. *Br J Cancer* 1957;11(3):359-77.
  7. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. *BMJ* 2000;320(7233):474-8.
  8. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. *Cancer* 1983;52(9):1551-7.
  9. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut* 2015;64(10):1637-49. doi: 10.1136/gutjnl-2014-309086
  10. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. *Cochrane Database Syst Rev* 2015(12):CD011134. doi: 10.1002/14651858.CD011134.pub2
  11. Sun W, Liu Y, Shou D, et al. AFP (alpha fetoprotein): who are you in gastrology? *Cancer Lett* 2015;357(1):43-6. doi: 10.1016/j.canlet.2014.11.018
  12. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. *Cancer Res* 2007;67(10):4553-5. doi: 10.1158/0008-5472.CAN-07-0563
  13. Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and

- mRNA degradation by miRNAs and siRNAs. *Genes Dev* 2006;20(5):515-24. doi: 10.1101/gad.1399806
14. Rokkas T, Kothonas F, Rokka A, et al. The role of circulating microRNAs as novel biomarkers in diagnosing colorectal cancer: a meta-analysis. *Eur J Gastroenterol Hepatol* 2015;27(7):819-25. doi: 10.1097/MEG.0000000000000363
15. Yang X, Zhong J, Ji Y, et al. The expression and clinical significance of microRNAs in colorectal cancer detecting. *Tumour Biol* 2015;36(4):2675-84. doi: 10.1007/s13277-014-2890-0
16. Liang Y, Yang W, Zhu Y, et al. Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies. *Springerplus* 2016;5(1):1538. doi: 10.1186/s40064-016-3225-y
17. Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microRNA-21 in gastric cancer: a meta-analysis. *Med Sci Monit* 2014;20:1668-74. doi: 10.12659/MSM.892096
18. Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. *J Int Med Res* 2013;41(3):596-602. doi: 10.1177/0300060513485856
19. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. miRNA biogenesis: biological impact in the development of cancer. *Cancer Biol Ther* 2014;15(11):1444-55. doi: 10.4161/15384047.2014.955442
20. Cho WC. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. *Front Genet* 2011;2:7. doi: 10.3389/fgene.2011.00007
21. Avery-Kiejda KA, Braye SG, Mathe A, et al. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. *BMC Cancer* 2014;14:51. doi: 10.1186/1471-2407-14-51
22. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and

- 1  
2  
3 numerous roles in health and disease. *Cell Death Differ*  
4 2013;20(12):1603-14. doi: 10.1038/cdd.2013.125  
5  
6  
7 23. Mendell JT. miRiad Roles for the miR-17-92 Cluster in Development and  
8 Disease. *Cell* 2008;133(2):217-22.  
9  
10 24. Wang Q, Li YC, Wang J, et al. miR-17-92 cluster accelerates adipocyte  
11 differentiation by negatively regulating tumor-suppressor Rb2/p130.  
12 *Proceedings of the National Academy of Sciences* 2008;105(8):2889.  
13  
14 25. Ottman R, Levy J, Grizzle WE, et al. The other face of miR-17-92a cluster,  
15 exhibiting tumor suppressor effects in prostate cancer. *Oncotarget*  
16 2016;7(45):73739.  
17  
18 26. Virginie Olive IJ, Lin He. mir-17-92, a cluster of miRNAs in the midst of the  
19 cancer network. *International Journal of Biochemistry & Cell Biology*  
20 2010;42(8):1348-54.  
21  
22 27. Shu T, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster  
23 in anaplastic thyroid cancer cells. *Cancer Science* 2008;99(6):1147-54.  
24  
25 28. Y H, H O, Y T, et al. A polycistronic microRNA cluster, miR-17-92, is  
26 overexpressed in human lung cancers and enhances cell proliferation.  
27 *Cancer Research* 2005;65(21):9628-32.  
28  
29 29. Griffiths-Jones S. The microRNA Registry. 2004  
30  
31 30. Kozomara A, Griffithsjones S. miRBase: annotating high confidence  
32 microRNAs using deep sequencing data. *Nucleic Acids Research*  
33 2014;42(Databaseissue):68-73.  
34  
35 31. Kozomara A, Griffithsjones S. miRBase: integrating microRNA annotation and  
36 deep-sequencing data. *Nucleic Acids Research* 2011;39(Database  
37 issue):D152-7.  
38  
39 32. Griffithsjones S, Grocock RJ, Dongen SV, et al. miRBase: microRNA  
40 sequences, targets and gene nomenclature. *Nucleic Acids Research*  
41 2006;34(suppl 1):140-4.  
42  
43 33. Griffithsjones S, Saini HK, Van DS, et al. miRBase: tools for microRNA  
44 genomics. *Nucleic Acids Research* 2008;36(Database issue):154-8.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59



- 1  
2  
3  
4 34. Zheng JJ, Dong PH, Gao SM, et al. High Expression of Serum miR-17-5p  
5 Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.  
6 *Hepato-Gastroenterology* 2013;60(123):549-52. doi: 10.5754/hge12754  
7  
8  
9 35. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts  
10 poor prognosis in human glioma. *Journal of biomedicine & biotechnology*  
11 2012;2012:970761. doi: 10.1155/2012/970761 [published Online First:  
12 2012/12/12]  
13  
14  
15 36. Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA miR-17-5p is overexpressed  
16 in pancreatic cancer, associated with a poor prognosis, and involved in  
17 cancer cell proliferation and invasion. *Cancer Biology & Therapy*  
18 2010;10(8):748.  
19  
20  
21 37. Xu XL, Jiang YH, Feng JG, et al. MicroRNA-17, microRNA-18a, and  
22 microRNA-19a are prognostic indicators in esophageal squamous cell  
23 carcinoma. *Annals of Thoracic Surgery* 2014;97(3):1037-45.  
24  
25  
26 38. Chen L, Jiang M, Yuan W, et al. miR-17-5p as a novel prognostic marker for  
27 hepatocellular carcinoma. *Journal of investigative surgery : the official*  
28 *journal of the Academy of Surgical Research* 2012;25(3):156-61. doi:  
29 10.3109/08941939.2011.618523 [published Online First: 2012/05/16]  
30  
31  
32 39. Robaina MC, Faccion RS, Mazzoccoli L, et al. miR-17-92 cluster components  
33 analysis in Burkitt lymphoma: overexpression of miR-17 is associated with  
34 poor prognosis. *Annals of Hematology* 2016;95(6):881-91.  
35  
36  
37 40. Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impact of  
38 disseminated tumor cells and microRNA-17-92 cluster deregulation in  
39 gastrointestinal cancer. *International Journal of Oncology* 2011;39(5):1253.  
40  
41  
42 41. Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in  
43 lung cancer. *Medical Oncology* 2013;30(1) doi:  
44 10.1007/s12032-012-0353-2  
45  
46  
47 42. Yu G, Tang JQ, Tian ML, et al. Prognostic values of the miR-17-92 cluster and  
48 its paralogs in colon cancer. *Journal of Surgical Oncology*  
49 2012;106(3):232-37. doi: 10.1002/jso.22138  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 43. Li X, Yang H, Tian Q, et al. Upregulation of microRNA-17-92 cluster  
5 associates with tumor progression and prognosis in osteosarcoma.  
6 *Neoplasma* 2014;61(4):453-60. doi: 10.4149/neo\_2014\_056  
7  
8  
9 44. Xi YF, Li J, Zhang P, et al. Upregulation of miRNA-17 and miRNA-19 is  
10 associated with unfavorable prognosis in patients with T-cell lymphoblastic  
11 lymphoma. *Experimental and Molecular Pathology* 2015;99(2):297-302.  
12 doi: 10.1016/j.yexmp.2015.07.012  
13  
14  
15 45. Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular  
16 markers for gastric cancer. *Mol Med Rep* 2012;5(6):1514-20. doi:  
17 10.3892/mmr.2012.828  
18  
19  
20 46. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform  
21 meta-analyses of the published literature for survival endpoints. *Stat Med*  
22 1998;17(24):2815-34.  
23  
24  
25 47. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies  
26 in epidemiology: a proposal for reporting. Meta-analysis Of Observational  
27 Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283(15):2008-12.  
28  
29  
30 48. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a  
31 simple, graphical test. *BMJ* 1997;315(7129):: 629–34.  
32  
33  
34 49. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for  
35 publication bias. *Biometrics* 1994;50(4):1088-101.  
36  
37  
38 50. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of  
39 testing and adjusting for publication bias in meta-analysis. *Biometrics*  
40 2000;56(2):455-63.  
41  
42  
43 51. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts  
44 poor prognosis in human glioma. *Biomed Research International*  
45 2012;2012(2012):970761.  
46  
47  
48 52. Chang CC, Yang YJ, Li YJ, et al. MicroRNA-17/20a functions to inhibit cell  
49 migration and can be used a prognostic marker in oral squamous cell  
50 carcinoma. *Oral Oncology* 2013;49(9):923-31.  
51  
52  
53 53. Li S, Gao Y, Wang Y, et al. Serum microRNA-17 functions as a prognostic  
54  
55  
56  
57  
58  
59

- biomarker in osteosarcoma. *Oncology Letters* 2016;12(6):4905-10.
54. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma. *Jama* 2008;299(4):425-36.
55. Yang F, Yin Y, Wang F, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. *Hepatology* 2010;51(5):1614–23.
56. Wang M, Gu H, Qian H, et al. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. *European Journal of Cancer* 2013;49(8):2010.
57. Ma Y, Zhang P, Wang F, et al. Elevated oncofetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. *Nature Communications* 2012;3(4):1291.
58. Yan HJ, Liu WS, Sun WH, et al. miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. *Digestive Diseases and Sciences* 2012;57(12):3160-67.

#### Figure legends

Figure 1 Flow diagram of the studies selection phase

Figure 2 Forest plots of meta-analysis of overall survival in association with miR-17 expression.

Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression.

(A) Forest plots of the merged analyses of OS in the different ethnic groups. Squares and lines correspond to the study-specific HRs and 95% CIs, respectively. The area of the squares represents the weight, and the diamond represent the summary of HRs and 95% CIs.

(B) Forest plots of the merged analyses of OS in the different diseases groups.

(C) Forest plots of the merged analyses of OS in the different RNA detection method groups.

(D) Forest plots of the merged analyses of OS in the different sample groups.

1  
2  
3 Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in  
4 association with miR-17 expression.  
5  
6  
7

8 Figure 5  
9

10 (A) Funnel plot of merged analysis of OS comparing high or low expression of miR-17.  
11  
12 (B) Egger's plot of merged analysis of OS comparing high or low expression of miR-17.  
13

14 Table 1. A summary table of the meta-analysis  
15

16 Table 2 Subgroup analysis  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Flow diagram of the studies selection phase

296x419mm (300 x 300 DPI)




Figure 2 Forest plots of meta-analysis of overall survival in association with miR-17 expression.

210x161mm (144 x 144 DPI)




Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression.

378x322mm (144 x 144 DPI)

Only




Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in association with miR-17 expression.

232x152mm (144 x 144 DPI)






Figure 5 Funnel plot and Egger's plot of merged analysis of OS comparing high or low expression of miR-17.

444x161mm (144 x 144 DPI)

Peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** A summary table of the meta-analysis

Study ID	Year	Country	Diseases	Case Number	Stage	Sample	Assay	Cut-off value	HR	Follow-up (months)
Chen et al	2012	China	HCC	120	I-IV	Tissue	qRT-PCR	Median	RR	46
Qun et al	2013	China	Lung Cancer	221	I-IV	Tissue	qRT-PCR	Median	Given	50
Li et al	2014	China	Osteosarcoma	117	I-III	Tissue	qRT-PCR	Median	Given	44
Lu et al	2012	China	Glioma	108	I-IV	Tissue	qRT-PCR	Mean	RR	60
Xi et al	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	Given	Up to 13 years
Yu et al	2012	China	Colon Cancer	48	I-IV	Tissue	qRT-PCR	Median	Given	5-66
Manuel et al	2011	Spain	Gastrointestinal Cancer	38	I-IV	Tissue	qRT-PCR	Mean	Given	38
Robaina et al	2016	Brazil	Burkitt lymphoma	41	I-IV	Tissue	ISH	Median	Given	69
Xu et al	2014	China	Esophageal Squamous Cell Carcinoma	105	I-IV	Tissue	qRT-PCR	Mean	Given	52
Jun et al	2010	Japan	Pancreatic Cancer	80	I-IV	Tissue	qRT-PCR	Median	Given	60
Wang et al	2011	China	Gastric Cancer	65	I-IV	Serum	qRT-PCR	Median	Given	36
Zheng et al	2013	China	HCC	96	I-IV	Serum	qRT-PCR	Median	Given	NG

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Abbreviations:** miR-17, microRNA-17; HCC, Hepatocellular Carcinoma; ISH, in situ hybridization; qRT-PCR, quantitative real-time polymerase chain reaction; RR, risk ratio; OS, overall survival; DFS, disease-free survival; NG, not given.

For peer review only

Subgroup	N	Heterogeneity		pHR(95% CI)	P-value
		$I^2$	P-value		
<b>Total</b>	12	0.382	0.086	1.42(1.30-1.55)	<0.001
<b>Ethnic subtotal</b>					
Caucasian	2	0.716	0.060	1.48(1.21-1.81)	<0.001
Asian	10	0.361	0.120	1.40(1.27-1.55)	<0.001
<b>Disease subtotal</b>					
Digestive system cancers	7	0.348	0.163	1.36(1.22-1.51)	<0.001
Non-digestive system cancers	5	0.269	0.233	1.54(1.33-1.78)	<0.001
<b>Detected method subtotal</b>					
qRT-PCR	11	0.290	0.169	1.40(1.28-1.53)	<0.001
ISH	1			2.59(1.39-4.81)	0.003
<b>Detected Sample subtotal</b>					
Tissue	10	0.462	0.053	1.45(1.31-1.61)	<0.01
Serum	2	0	0.662	1.32(1.10-1.57)	0.002

Table 2 Subgroup analysis

**Abbreviations:** pHR, pooled hazard ratio; qRT-PCR, quantitative real-time polymerase chain reaction; ISH, in situ hybridization.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	1
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	9
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018070.R1
Article Type:	Research
Date Submitted by the Author:	23-Feb-2018
Complete List of Authors:	Huang, Chengzhi; Shantou University, Medical College; Guangdong General Hospital, Department of General Hospital Yu, Mengya; Guangdong General Hospital, Department of General Hospital; Southern Medical University Yao, Xueqing; Guangdong General Hospital; Shantou University, Medical College
<b>Primary Subject Heading</b>:	Genetics and genomics
Secondary Subject Heading:	Gastroenterology and hepatology, Oncology, Pathology, Surgery
Keywords:	microRNA-17, Cancer, Outcome, Prognosis, Meta-analysis

SCHOLARONE™  
Manuscripts



## MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis

Chengzhi Huang<sup>1,2</sup>, Mengya Yu<sup>2,3</sup>, Xueqing Yao<sup>1,2,3#</sup>

1 Medical College, Shantou University, Shantou, Guangdong, China.

2 Department of General Surgery, Guangdong General Hospital (Guangdong Academy of Medical Sciences),  
Guangzhou, Guangdong, China.

3 Southern Medical University, Guangzhou, Guangdong, China.

# To whom correspondence should be addressed:

Xueqing Yao

No.106 Zhongshaner Road, Guangzhou, Guangdong, China, 510000.

Phone: 020-83827812

Fax: 020-83827812

Email: [yjb9211@21cn.com](mailto:yjb9211@21cn.com)

## Abstract

**Objective** The role of microRNA-17(miR-17) has been identified as a tumor biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyze and summarize the relationship between the miR-17 status and clinical outcome in a variety of human cancers.

**Design** Systematic review and meta-analysis.

**Data sources** PubMed, Web of Science, and Embase from the first year of records through May 15th, 2017

**Outcomes** The patients' survival results were pooled, and pooled hazard ratio (HR) with 95% confidential intervals were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma, and colon cancer. Heterogeneity, publication bias, and subgroup analysis were also conducted.

**Results** A total of 1096 patients were included in this meta-analysis from 12 articles. The results indicated that the increased expression of miR-17 played an unfavorable role in overall survival (OS) in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38), detection method (qRT-PCR HR=1.40 and in situ hybridization, ISH HR=2.59), and detection sample (tissue HR=1.45 and serum HR=1.32) were significant with  $p < 0.05$ . For the analysis of disease-free survival and recurrence-free survival, the increased expression of miR-17 was associated with unfavorable prognosis (HR=1.40).

**Conclusions** miR-17 may be a useful biomarker in predicting the clinical outcome of human cancers, but due to the limitations of the current studies, further verification of the role of miR-17 in human malignancies is urgently needed.

**Keywords** microRNA-17; Cancer; Outcome; Prognosis; Meta-analysis.

## Strengths and limitations of the study

1. This is the first meta-analysis that summarized and reported the microRNA-17 as a novel potential cancer prognostic biomarker in the clinical field.
2. We used strict, broad search strategy of the internet databases to minimize any potential publication bias.
3. We conducted the subgroup analysis and found that the up-regulated expression of microRNA-17 may imply poor clinical outcome in digestive system cancers.
4. The major limitation of our meta-analysis is the inclusion of a limited number of studies carried out on Western populations decreasing the applicability of our results among other ethnicities. MicroRNA-17

1 detection is not routine clinical practice, and the prognostic value of microRNA-17 remains controversial. In  
2 the future, additional clinical trials are needed to verify the prognostic significance of microRNA 17.  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction

Despite significant advances in clinical research over the past few decades, cancer is still a key health burden and a leading cause of death worldwide. In the year 2017, it is estimated that 1,688,780 patients were diagnosed with cancers with 600,920 cancer deaths in the United States<sup>1</sup>. Due to the advanced screening methods and adjuvant systemic therapies for newly diagnosed cases, the mortality rate for cancers is declining in the developed countries<sup>2</sup>, whereas the clinical outcome of cancers in the developing countries is still poor<sup>3,4</sup>.

There are several independent factors for identifying and evaluating the clinical outcome of human cancers, including tumor size, histological grade, age of the patients, and metastasis to lymph nodes<sup>5-8</sup>. Tissue- and serum-based tumor biomarkers are widely used to predict the prognosis of neoplasms. However, these techniques are far from satisfactory due to the low specificity and sensitivity<sup>9-11</sup>. Thus, a less-invasive and more accurate biomarker would be of great value for the prognosis of human tumors.

The discovery of microRNAs (miRNAs) provided an innovative method for the prognosis of cancers by a less-invasive detection method<sup>12</sup>. miRNAs, a class of endogenous non-coding single-stranded RNAs with the length of 18-25 nucleotides, act as regulators of gene expression by pairing with the complementary nucleotides in the 3'-untranslated regions (3'-UTR) of their target mRNAs. miRNAs may act as regulators of cell growth, proliferation, differentiation and apoptosis<sup>13</sup>. Because of these fundamental activities, numerous studies have shown that miRNAs function as tumor suppressors or oncogenes. It has also been reported that some miRNAs are differentially expressed between tumor and non-tumor tissues, and the abnormal expression of tumor-associated miRNAs can be detected in patient's blood, cancerous tissue and fecal samples<sup>14,15</sup>. Recent studies have demonstrated that aberrantly expressed miRNAs, especially those acting as tumor suppressors or oncogenes, are related to cancer development, progression, and patients' response to therapy<sup>16-18</sup>. Therefore, miRNAs can be considered as useful prognostic biomarkers for various human cancers.

One such example is of miR-17 that is aberrantly expressed in cancer patients<sup>19-21</sup>. The miR-17 family, which includes six members, is one of the most extensively studied miRNA clusters<sup>22</sup>. These miRNAs are located within an 800 base-pair region of human chromosome 13, play an essential role in the development of the heart, lung, and human immune system<sup>23</sup>. Recent studies have found that miR-17 may play a critical role in the development of human cancers.<sup>24,25</sup> Increased expression of miR-17 promotes the metastasis of lung and pancreatic cancers, suggesting its role as an oncogene<sup>26,27</sup>. However, other studies have reported that miR-17 inhibits tumor cell invasion and metastasis in breast cancer<sup>28</sup>. In all, the role of miR-17 in cancer development as well as the exact mechanism are not yet clearly described. According to the miRBase (<http://www.mirbase.org>), miR-17 includes two members, miR-17-5p and miR-17-3p which are located in the sequence of miR-17 with a stem-loop structure. As a result, the detection of miR-17-5p, miR-17-3p has the same effect and result of detecting miR-17<sup>29-33</sup>.

Several published results indicate that the higher expression of the miR-17 is indicative of poor prognosis in cancer patients<sup>26 27 34-43</sup>. However, several confounding factors, including race, detection method, and tumor site, may affect the observations making the relationship between aberrant expression of miR-17 and the clinical outcome of cancer patients inconsistent. We, therefore, conducted a meta-analysis of available studies to evaluate the clinical utility of miR-17 as a novel cancer prognostic indicator.

## Material and Methods

### Data Source and Search Strategy

The following online electronic databases were used for the literature search: PubMed, Web of Science, and Embase. The search period was up to May 15th, 2017. Key search words used were: (1) prognosis OR prognostic OR survival OR outcome OR mortality; (2) cancer OR tumor OR tumour OR carcinoma OR neoplasm; (3) miR-17 OR microRNA-17 OR hsa-mir-17. Details are listed in the Supplementary Table 1. Additionally, we also searched the references and relevant published articles via Google Scholar.

### Inclusion and Exclusion Criteria

The inclusion criteria of the articles were: (1) the cancers were diagnosed by the histological examination or any other accepted standard; (2) miR-17 was studied in human cancers; (3) the expression of miR-17 and the clinical outcome of patients were included in the research; and (4) reports with survival outcome and the data analyzed hazard ratio (HR) with 95% confidence interval (95% CI) and HR with a *P*-value.

The exclusion criteria were: (1) duplicate publications; (2) articles focused on other genes; (3) case reports, reviews, letters, and animal trials; (4) unqualified or insufficient data; (5) HR, 95% CI and *P*-value were not provided or could not be calculated and (6) articles concentrated on the polymorphisms or methylation patterns of miRNAs.

Questions of suitability of articles to be included were examined and discussed by the authors after reviewing the abstract and full text manuscript. The final decision was made by the academic committee.

### Data extraction and quality assessment

All included studies were decided by the two investigators (Huang and Yao) independently based on titles and abstracts. Full-text of the articles was required if the articles were potentially suitable for the meta-analysis. Furthermore, the literature search was performed again in the excluded articles to avoid missing any article potentially relevant for the study. The original authors of the articles were contacted if any supplementary data were needed. Any disagreement was resolved by the two authors (Huang and Yao). The extracted details of the articles were as follows: (1) publication information: the name of the authors, publication area, and publication year; (2) patient's characteristics: diseases, stage of the disease, RNA detection method, type of tissue sample

and follow-up years; (3) the measurement of miR-17 measurement and its cut-off value and (4) HR of miR-17 for overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS), as well as their 95% CI and *P*-values. The HRs and their 95% CI were extracted from the original articles or via e-mails from the authors. If not, we calculated HR and 95% CI using the data of observed deaths, cancer recurrences, or the original data provided by the authors. All calculations mentioned above were based on the methods provided by Parmar, M. K. et al.<sup>44</sup>. The quality of the included articles was assessed based on a systematic review checklist of the Dutch Cochrane Centre proposed by MOOSE<sup>45</sup>.

## Statistical Analysis

The test of heterogeneity of pooled HRs was carried out by using Cochran's *Q*-test and Higgins *I*<sup>2</sup> statistic. A *P*-value of < 0.05 or *I*<sup>2</sup> > 50% was considered as statistically significant. The 95%CI of *I*<sup>2</sup> was calculated by the method introduced by Hedges et al<sup>46</sup>. If heterogeneity existed, the random effects model was performed among the included studies; otherwise, the fixed effects model was selected. *I*<sup>2</sup> value ranged from 0% to 100%. All *P*-values were two-sided.

HR >1 presents of up-regulated expression of miR-17 indicated poor prognosis in patients, and HR <1 suggested a better prognosis. Publication bias was evaluated by the Begg's test and Egger's test<sup>47 48</sup>. If the publication bias did exist, the trim and fill method introduced by Duval and the Tweedit's was used to adjust the results<sup>49</sup>. The STATA software Version 14.0 (StataCorp LP, College Station, TX, USA) was used in all of the statistical analyses.

## Study registration

The systematic review and meta-analysis is registered in PROSPERO (No. CRD42017065749).

## Patients and Public Involvement Statement

The patients or public were not involved in the study.

## Results

### Literature selection

We started with 405 articles associated with miR-17 and cancer prognosis was identified from online database searches. After removing the replicate records, 304 miR-17-related articles were left. The first screening based on the species, article type, and language eliminated 210 citations from the analysis. Subsequently, the remaining 104 studies were carefully assessed by reviewing the abstract and full text of each article. After that, 89 articles were excluded from the study because they were unrelated to miR-17 expression levels or because of the lack of survival statistics such as HRs, 95% CI, or *P*-value. Finally, 15 studies, which

investigated the potential relationship between miR-17 expression and prognosis of human cancers, remained for further detailed screening and data-extraction. Three of the studies that explained the relationship between miR-17 expression and the clinical outcome of cancer had to be removed because the authors did not provide the exact HR value, or the value cannot be calculated from the data. Thus, 12 articles (12 studies)<sup>26 27 34-43</sup> were included in this meta-analysis. (Figure 1)

### Characteristics of selected studies

All 12 studies included in the meta-analysis were retrospective studies published between 2010 and 2016<sup>26 27 34-43</sup>. Patient's OS was reported in all 12 studies, and three studies also examined the DFS or RFS. The type of the cancers included gastrointestinal cancers (colorectal cancer, gastric cancer), lung cancer, pancreatic cancer, hepatocellular cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and esophageal squamous cell carcinoma. Total of 1096 patients with various types of cancers were from People's Republic of China, Japan, Spain, and Brazil. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression of miR-17 in 12 studies, and one study used the in-situ hybridization (ISH). All studies used tissue and serum samples as the source of the miR-17. The majority (10 of 12) of the HRs reported in the present analysis were included in the multivariate analysis. The remaining two HRs could be estimated by Kaplan-Meier analysis and relative risk (RR) values. Most of the studies have the follow-up research for at least 38 months. The clinical characteristics of the studies included in this article are summarized in Table 1.

Study	Year	Country	Diseases	Case Number	Stage	Sample	Assay	Cut-off value	HR
Ren et al	2012	China	HCC	120	I-IV	Tissue	qRT-PCR	Median	1.0
Lin et al	2013	China	Lung Cancer	221	I-IV	Tissue	qRT-PCR	Median	1.0
Li et al	2014	China	Osteosarcoma	117	I-III	Tissue	qRT-PCR	Median	1.0
Yu et al	2012	China	Glioma	108	I-IV	Tissue	qRT-PCR	Mean	1.0
Li et al	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	1.0
Yu et al	2012	China	Colon Cancer	48	I-IV	Tissue	qRT-PCR	Median	1.0
Munoz et al	2011	Spain	Gastrointestinal Cancer	38	I-IV	Tissue	qRT-PCR	Mean	1.0
Almeida et al	2016	Brazil	Burkitt lymphoma	41	I-IV	Tissue	ISH	Median	1.0
Yu et al	2014	China	Esophageal Squamous Cell Carcinoma	105	I-IV	Tissue	qRT-PCR	Mean	1.0
Yan et al	2010	Japan	Pancreatic Cancer	80	I-IV	Tissue	qRT-PCR	Median	1.0
Yang et al	2011	China	Gastric Cancer	65	I-IV	Serum	qRT-PCR	Median	1.0
Weng et al	2013	China	HCC	96	I-IV	Serum	qRT-PCR	Median	1.0

### Association between miR-17 and OS

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Due to low heterogeneity, fixed effects model was used to calculate and analyze the pooled HR value. High expression level of miR-17 was associated with the poor OS in patients with diverse cancers. The statistical power of  $Q$ -test is low when there are limited studies included in the meta-analysis. We, therefore, conducted random effect analysis on the OS (HR=1.45, 95%CI=1.29-1.63,  $P<0.001$ ), which was not significantly different compared to the analysis of fixed effect model. Details of the meta-analysis are systematically summarized in the Figure 2.

To demonstrate the predictive role of miR-17, subgroups analysis was conducted based on patients'

Subgroup	Number of studies	Heterogeneity		pooled HR (95% CI)	P-value
		$I^2$ (95%CI)	P-value		
<b>Total</b>	12	38.2% (0%-68.7%)	0.086	1.42(1.30-1.55)	<0.001
<b>Ethnic subtotal</b>					
Caucasian	2	71.6% (0%-93.6%)	0.06	1.48(1.21-1.81)	<0.001
Asian	10	36.1% (0%-69.5%)	0.12	1.40(1.27-1.55)	<0.001
<b>Disease subtotal</b>					
Digestive system	7	34.8% (0%-72.4%)	0.163	1.36(1.22-1.51)	<0.001
Respiratory system	1	NA	NA	1.28(1.02-1.61)	0.036
Blood system	2	0	0.713	2.38(1.56-3.63)	<0.001
Glioma	1	NA	NA	1.61(1.19-2.18)	0.002
Osteosarcoma	1	NA	NA	1.61(1.19-2.18)	<0.001
<b>Detected method subtotal</b>					
qRT-PCR	11	29.0% (0%-65.0%)	0.169	1.40(1.28-1.53)	<0.001
ISH	1	NA	NA	2.59(1.39-4.81)	0.003
<b>Detected Sample subtotal</b>					
Tissue	10	46.2% (0%-74.1%)	0.053	1.45(1.31-1.61)	<0.001
Serum	2	0	0.662	1.32(1.10-1.57)	0.002
<b>Detection of miR-17 subtotal</b>					
miR-17	8	60.1% (13.2%-81.7%)	0.057	1.29(1.11-1.49)	<0.001
miR-17-5p	4	7.5% (0%-43.4%)	0.372	1.50(1.34-1.67)	0.001

ethnicity, cancer type, methods identifying miRNAs and type of tissue samples. Clinical association between miR-17 and OS was found in the Asian and Caucasian patients. The association was also significant in other subgroups, including digestive system cancers and blood cancers, qRT-PCR detection method, and tissue and serum samples. miR-17 includes two members, miR-17-5p and miR-17-3p which are located in the sequence of miR-17 with a stem-loop structure. Therefore, analysis of miR-17-5p or miR-17-3p afforded the same effect (or result) as miR-17. To clarify the heterogeneity, we conducted a subgroup analysis concerning the detection method of miR-17 and found that the clinical value was also significant in miR-17 group and miR-17-5p group. There was no significant difference between the two groups (Figure 3E), implying that same effect existed when detecting miR-17 and miR-17-5p. Details of the subgroup analysis are listed in the Table 2

### Correlation between miR-17 and DFS and RFS



A total of 3 studies<sup>37 38 41</sup> were included in the analysis of DFS and RFS. The analyses revealed a predictive role of increased expression of miR-17 for the prognosis of cancer patients (pooled HR= 1.40, 95% CI=1.23-1.60,  $P<0.001$ ) as determined by the fix-effect model ( $I^2=15.8\%$ ,  $P=0.305$ ) (Figure 4).

### Publication bias

We used Begg's funnel plot and Egger's test to assess the possible publication bias of the included studies<sup>47 48</sup>. In the analysis of relationship between miR-17 and the OS, the  $P$ -values of Egger's test and Begg's test were 0.014 and 0.011, respectively. The funnel plot and Egger's plot are displayed in Figure 5. Both Begg's test and Egger's test implied a publication bias, thus the trim and fill method was performed to make pooled HR more reliable<sup>49</sup>. The altered HR was 1.34, 95% CI=1.24-1.46,  $P<0.001$ , which was not significantly different from the pooled HR (Supplementary Figure 1).

### Discussion

Previous studies have shown that miRNAs have a distinct expression profile in cancerous tissues which can be detected by qRT-PCR in frozen, formalin-fixed, and paraffin-embedded tissues and in serum samples. Recently, miRNAs, serving as tumor suppressors or oncogenes, have been shown to play important roles in the evolution and progression of cancers. miRNAs are involved in a variety of crucial cellular pathways such as angiogenesis, innate and adaptive immune responses, cellular proliferation, invasion, and metastasis.<sup>12 16</sup> Several studies have reported the potential use of miRNAs as tumor biomarkers for detecting tumor occurrence, development, and prognosis. Unfortunately, effective diagnosis techniques and prognosis indicators of cancer have not been found. Developing a novel less-invasive detection method with higher accuracy for cancer prognosis is of great significance in evaluating cancer progression as well as monitoring patients' therapeutic response.

Over the last couple of decades, numerous studies have uncovered the involvement of miRNAs in the pathogenesis of cancer. Since miRNAs can be obtained noninvasively from the serum, urine, and fecal samples, their utility as diagnostic and prognostic biomarkers in cancer and other diseases has been extensively explored. It has been reported that miRNA could be detected with higher accuracy than traditional cancer biomarkers in predicting the clinical outcome of the human colon cancers<sup>50</sup>. However, adequate evidence is still lacking for the utility of miRNAs as cancer biomarkers in clinical practice.

miR-17, a widely-studied miRNA, is aberrantly expressed in different kinds of cancers, such as glioma<sup>51</sup>, esophageal and oral squamous cell carcinomas<sup>36 52</sup>, pancreatic cancer<sup>26</sup>, gastrointestinal cancers<sup>39</sup>, osteosarcoma<sup>53</sup> and Burkitt lymphoma<sup>38</sup>, and is significantly related to the clinical outcome of cancers. Our meta-analysis indicated that the elevated miR-17 expression is significantly associated with poor OS (HR=1.42) in patients with various types of carcinomas. The analysis using the Cochran's  $Q$ -test and Higgins  $I^2$  test

1 implied low heterogeneity. As limited number of studies were included in the meta-analysis, the  $Q$ -test had  
2 inadequate statistical power. We, therefore, applied the fixed effects model to calculate and analyze the pooled  
3 HR value. We also conducted random effect analysis on the OS, which was not significantly different when  
4 compared to analysis of fixed effect model (Figure 2). In the subgroup analysis, we found that the potential  
5 heterogeneity may have originated from the Caucasian group in the study conducted by Robaina et al.<sup>38</sup>. Unlike  
6 the commonly used RT-PCR, ISH technique was used to detect miR-17. Other factors contributing to the  
7 heterogeneity in the study may include absence of Hispanics in the Brazilian study and the limited number of  
8 patients (n=41) recruited in the study.

9 As the Begg's test and the Egger's test implied publication bias, we used the Trim and Fill method to  
10 obtain a more reliable pooled HR. We found that the adjusted HR was not significantly different from the  
11 pooled HR. In subgroup analysis, based on the characteristics of the individual studies, significant HR was  
12 found in the Caucasian and Asian groups, the qRT-PCR group and the tissue and serum sample groups.  
13 Furthermore, the increased expression of miR-17 indicated poor DFS and RFS in HCC and gastrointestinal  
14 cancers. Several investigators have explored the functional roles of miR-17 and its involvement in human  
15 cancers. Yang et al. found that the miRNA-17 was overexpressed in the HCC tissue, and promoted the  
16 phosphorylation of heat shock protein 27 (HSP27). The phosphorylated HSP27 then enhanced the migration of  
17 the HCC cells implying a significant role of miRNA-17 in the progression of HCC<sup>54</sup>. Wang et al. reported that  
18 the up-regulated expression of miRNA-17-5p promoted cancer cells proliferation and inhibited apoptosis by  
19 post-transcriptional modulation of mRNA p21 and tumor protein p53-induced nuclear protein 1 (TP53INP1)<sup>55</sup>.  
20 In the study by Ma et al. overexpression of miRNA-17 promoted cancer cells progression by targeting P130<sup>56</sup>.  
21 Yan et al. found over-expression of the miR-17-5p in pancreatic cancer. The miR-17-5p inhibitor promoted the  
22 expression of Bim protein by targeting the 3'-untranslated regions of its mRNA and negatively regulating at the  
23 posttranscriptional level. Therefore, the authors suggested that the miR-17-5p inhibitor may be a novel  
24 therapeutic approach for pancreatic cancer<sup>57</sup>. Together with our meta-analysis, these findings suggest that the  
25 detection of tissue or serum miR-17 expression may be a useful prognostic biomarker in patients with HCC,  
26 pancreatic cancer, and gastrointestinal cancers.

27 There are potential limitations of this study. The literature searches using authentic and widely used data  
28 bases found studies performed predominantly on Asian populations not encompassing sufficient numbers of  
29 other populations such as Caucasians. Our results of miR-17 as a potential biomarker may, therefore, not be  
30 applicable to other populations. The pooled HR values were also not sufficiently strong. Furthermore, the  
31 relatively limited sample size of 1031 patients weakened the statistical significance of the prognostic potential  
32 of miR-17 expression levels.

## 33 Conclusions

In summary, our meta-analysis suggested that miR-17 is a potential biomarker in various types of cancers. However, further multi-center clinical trials with larger sample size and prospective studies including Caucasians and patients representing other ethnicities are needed to confirm the prognostic value of miR-17 and its subsequent application as a prognostic biomarker in the routine clinical guidance of cancers.

## Acknowledgments

Not applicable.

## Contributors

Chengzhi Huang and Mengya Yu conceived the study. Chengzhi Huang and Xueqing Yao performed the data extraction and analysed the data. Chengzhi Huang and Mengya Yu wrote the paper. All authors had full access to all of the data and approved the final version of manuscript.

## Disclosure of conflicts

The authors report no conflicts of interest in this work.

## Data Sharing Statement

No additional data are available

## Funding

The article is funded by Guangdong Science and Technology Department, China. (No.2014A020212636).

## Ethics approval

The study does not include human participants or animals.

## Patients and Public Involvement Statement

The patients or public were not involved in the study.

## Reference

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67(1):7-30. doi: 10.3322/caac.21387
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65(2):87-108. doi: 10.3322/caac.21262

3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66(2):115-32. doi: 10.3322/caac.21338
4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012;62(4):220-41. doi: 10.3322/caac.21149
5. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. *Cancer* 1969;24(5):1071-80.
6. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. *Br J Cancer* 1957;11(3):359-77.
7. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. *BMJ* 2000;320(7233):474-8.
8. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. *Cancer* 1983;52(9):1551-7.
9. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut* 2015;64(10):1637-49. doi: 10.1136/gutjnl-2014-309086
10. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. *Cochrane Database Syst Rev* 2015(12):CD011134. doi: 10.1002/14651858.CD011134.pub2
11. Sun W, Liu Y, Shou D, et al. AFP (alpha fetoprotein): who are you in gastrology? *Cancer Lett* 2015;357(1):43-6. doi: 10.1016/j.canlet.2014.11.018
12. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. *Cancer Res* 2007;67(10):4553-5. doi: 10.1158/0008-5472.CAN-07-0563
13. Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev* 2006;20(5):515-24. doi: 10.1101/gad.1399806
14. Rokkas T, Kothonas F, Rokka A, et al. The role of circulating microRNAs as novel biomarkers in diagnosing colorectal cancer: a meta-analysis. *Eur J Gastroenterol Hepatol* 2015;27(7):819-25. doi: 10.1097/MEG.0000000000000363
15. Yang X, Zhong J, Ji Y, et al. The expression and clinical significance of microRNAs in colorectal cancer detecting. *Tumour Biol* 2015;36(4):2675-84. doi: 10.1007/s13277-014-2890-0
16. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. miRNA biogenesis: biological impact in the development of cancer. *Cancer Biol Ther* 2014;15(11):1444-55. doi: 10.4161/15384047.2014.955442
17. Cho WC. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. *Front Genet* 2011;2:7. doi: 10.3389/fgene.2011.00007

- 1 18. Avery-Kiejda KA, Braye SG, Mathe A, et al. Decreased expression of key tumour suppressor  
2 microRNAs is associated with lymph node metastases in triple negative breast cancer. *BMC*  
3 *Cancer* 2014;14:51. doi: 10.1186/1471-2407-14-51
- 4  
5 19. Liang Y, Yang W, Zhu Y, et al. Prognostic role of microRNA-203 in various carcinomas: evidence  
6 from a meta-analysis involving 13 studies. *Springerplus* 2016;5(1):1538. doi:  
7 10.1186/s40064-016-3225-y
- 8  
9 20. Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microRNA-21 in gastric cancer: a meta-analysis.  
10 *Med Sci Monit* 2014;20:1668-74. doi: 10.12659/MSM.892096
- 11  
12 21. Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association  
13 with disease characteristics and patient survival. *J Int Med Res* 2013;41(3):596-602. doi:  
14 10.1177/0300060513485856
- 15  
16 22. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics,  
17 genetics, functions and increasingly important and numerous roles in health and disease. *Cell*  
18 *Death Differ* 2013;20(12):1603-14. doi: 10.1038/cdd.2013.125
- 19  
20 23. Mendell JT. miRiad Roles for the miR-17-92 Cluster in Development and Disease. *Cell*  
21 2008;133(2):217-22.
- 22  
23 24. Wang Q, Li YC, Wang J, et al. miR-17-92 cluster accelerates adipocyte differentiation by  
24 negatively regulating tumor-suppressor Rb2/p130. *Proceedings of the National Academy of*  
25 *Sciences* 2008;105(8):2889.
- 26  
27 25. Ottman R, Levy J, Grizzle WE, et al. The other face of miR-17-92a cluster, exhibiting tumor  
28 suppressor effects in prostate cancer. *Oncotarget* 2016;7(45):73739.
- 29  
30 26. Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer,  
31 associated with a poor prognosis, and involved in cancer cell proliferation and invasion. *Cancer*  
32 *Biology & Therapy* 2010;10(8):748.
- 33  
34 27. Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. *Medical*  
35 *Oncology* 2013;30(1) doi: 10.1007/s12032-012-0353-2
- 36  
37 28. Yu Z, Koprowski H. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast  
38 cancer by heterotypic signaling. *Proceedings of the National Academy of Sciences of the*  
39 *United States of America* 2010;107(18):8231.
- 40  
41 29. Griffiths-Jones S. The microRNA Registry. 2004
- 42  
43 30. Kozomara A, Griffithsjones S. miRBase: annotating high confidence microRNAs using deep  
44 sequencing data. *Nucleic Acids Research* 2014;42(Databaseissue):68-73.
- 45  
46 31. Kozomara A, Griffithsjones S. miRBase: integrating microRNA annotation and deep-sequencing  
47 data. *Nucleic Acids Research* 2011;39(Database issue):D152-7.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 32. Griffithsjones S, Grocock RJ, Dongen SV, et al. miRBase: microRNA sequences, targets and gene  
2 nomenclature. *Nucleic Acids Research* 2006;34(suppl 1):140-4.  
3
- 4 33. Griffithsjones S, Saini HK, Van DS, et al. miRBase: tools for microRNA genomics. *Nucleic Acids*  
5 *Research* 2008;36(Database issue):154-8.  
6
- 7 34. Zheng JJ, Dong PH, Gao SM, et al. High Expression of Serum miR-17-5p Associated with Poor  
8 Prognosis in Patients with Hepatocellular Carcinoma. *Hepato-Gastroenterology*  
9 2013;60(123):549-52. doi: 10.5754/hge12754  
10
- 11 35. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts poor prognosis in  
12 human glioma. *Journal of biomedicine & biotechnology* 2012;2012:970761. doi:  
13 10.1155/2012/970761 [published Online First: 2012/12/12]  
14
- 15 36. Xu XL, Jiang YH, Feng JG, et al. MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic  
16 indicators in esophageal squamous cell carcinoma. *Annals of Thoracic Surgery*  
17 2014;97(3):1037-45.  
18
- 19 37. Chen L, Jiang M, Yuan W, et al. miR-17-5p as a novel prognostic marker for hepatocellular  
20 carcinoma. *Journal of investigative surgery : the official journal of the Academy of Surgical*  
21 *Research* 2012;25(3):156-61. doi: 10.3109/08941939.2011.618523 [published Online First:  
22 2012/05/16]  
23
- 24 38. Robaina MC, Faccion RS, Mazzoccoli L, et al. miR-17-92 cluster components analysis in Burkitt  
25 lymphoma: overexpression of miR-17 is associated with poor prognosis. *Annals of Hematology*  
26 2016;95(6):881-91.  
27
- 28 39. Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impact of disseminated tumor cells and  
29 microRNA-17-92 cluster deregulation in gastrointestinal cancer. *International Journal of*  
30 *Oncology* 2011;39(5):1253.  
31
- 32 40. Yu G, Tang JQ, Tian ML, et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon  
33 cancer. *Journal of Surgical Oncology* 2012;106(3):232-37. doi: 10.1002/jso.22138  
34
- 35 41. Li X, Yang H, Tian Q, et al. Upregulation of microRNA-17-92 cluster associates with tumor  
36 progression and prognosis in osteosarcoma. *Neoplasma* 2014;61(4):453-60. doi:  
37 10.4149/neo\_2014\_056  
38
- 39 42. Xi YF, Li J, Zhang P, et al. Upregulation of miRNA-17 and miRNA-19 is associated with  
40 unfavorable prognosis in patients with T-cell lymphoblastic lymphoma. *Experimental and*  
41 *Molecular Pathology* 2015;99(2):297-302. doi: 10.1016/j.yexmp.2015.07.012  
42
- 43 43. Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric  
44 cancer. *Mol Med Rep* 2012;5(6):1514-20. doi: 10.3892/mmr.2012.828  
45
- 46 44. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- published literature for survival endpoints. *Stat Med* 1998;17(24):2815-34.
45. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283(15):2008-12.
46. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. *Psychological Methods* 2001;6(3):203-17.
47. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7129):: 629–34.
48. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-101.
49. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56(2):455-63.
50. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma. *Jama* 2008;299(4):425-36.
51. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts poor prognosis in human glioma. *Biomed Research International* 2012;2012(2012):970761.
52. Chang CC, Yang YJ, Li YJ, et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. *Oral Oncology* 2013;49(9):923-31.
53. Li S, Gao Y, Wang Y, et al. Serum microRNA-17 functions as a prognostic biomarker in osteosarcoma. *Oncology Letters* 2016;12(6):4905-10.
54. Yang F, Yin Y, Wang F, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. *Hepatology* 2010;51(5):1614–23.
55. Wang M, Gu H, Qian H, et al. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. *European Journal of Cancer* 2013;49(8):2010.
56. Ma Y, Zhang P, Wang F, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. *Nature Communications* 2012;3(4):1291.
57. Yan HJ, Liu WS, Sun WH, et al. miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. *Digestive Diseases and Sciences* 2012;57(12):3160-67.

## Figure and table legends

Figure 1 Flow diagram of the studies selection phase

Figure 2 Forest plot of meta-analysis of overall survival in association with miR-17 expression.

Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression.

(A) Forest plots of the merged analyses of OS in different ethnic groups. Squares and lines correspond to the study-specific HRs and 95% CIs, respectively. The area of the squares represents the weight, and the diamonds represent the summary of HRs and 95% CIs.

(B) Forest plots of the merged analyses of OS in different diseases groups.

(C) Forest plots of the merged analyses of OS in different RNA detection methods groups.

(D) Forest plots of the merged analyses of OS in different sample groups.

(E) Forest plots of the merged analyses of OS in the detection method of miR-17.

Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in association with miR-17 expression.

Figure 5

(A) Funnel plot of merged analysis of OS comparing high or low expression of miR-17.

(B) Egger's plot of merged analysis of OS comparing high or low expression of miR-17.

Table 1. A summary table of the meta-analysis.

Abbreviations: miR-17, microRNA-17; HCC, hepatocellular carcinoma; ISH, in situ hybridization; qRT-PCR, quantitative real-time polymerase chain reaction; RR, risk ratio; OS, overall survival; DFS, disease-free survival; NG, not given.

Table 2 Subgroup analysis.

Abbreviations: miR-17, microRNA-17; miR-17-5p, microRNA-17-5p; qRT-PCR, quantitative real-time polymerase chain reaction; ISH, in situ hybridization; NA, not available.

Supplementary Table 1 The search strategy of online databases

Supplementary Figure 1 Funnel plot of adjusted pooled HRs after the analysis of the Trim and Fill method.

Supplementary Material 1 PRISMA 2009 checklist.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Flow diagram of the studies selection phase

193x206mm (300 x 300 DPI)




Figure 2 Forest plots of meta-analysis of overall survival in association with miR-17 expression.

210x161mm (300 x 300 DPI)




Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression. (A) Forest plots of the merged analyses of OS in different ethnic groups. Squares and lines correspond to the study-specific HRs and 95% CIs, respectively. The area of the squares represents the weight, and the diamonds represent the summary of HRs and 95% CIs.

(B) Forest plots of the merged analyses of OS in different disease groups.

(C) Forest plots of the merged analyses of OS in different RNA detection methods groups.

(D) Forest plots of the merged analyses of OS in different sample groups.

(E) Forest plots of the merged analyses of OS in the detection method of miR-17.

233x299mm (300 x 300 DPI)




Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in association with miR-17 expression.

190x124mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 5  
 (A) Funnel plot of merged analysis of OS comparing high or low expression of miR-17.  
 (B) Egger's plot of merged analysis of OS comparing high or low expression of miR-17.

209x81mm (300 x 300 DPI)

Peer review only

# Filled funnel plot with pseudo 95% confidence limits



**Supplementary Table 1 The search strategy of online databases**

<b>Databases</b>	<b>Search method</b>
Pubmed	("MIRN17 microRNA, human" [Supplementary Concept] AND "Neoplasms"[Mesh] AND "Prognosis"[Mesh])
Web of Science	
1	TS=(cancer OR neoplas* OR carcinom* OR tumo*)
2	TS=(prognosis OR prognostic OR survival OR outcome OR mortality)
3	TS=(miR-17 OR microRNA-17 OR hsa-mir-17)
4	#1 AND #2 AND #3
Embase	
1	miR-17 OR microRNA-17 OR hsa-mir-17
2	cancer OR neoplas* OR carcinom* OR tumo*
3	prognosis OR prognostic OR survival OR outcome OR mortality
4	#1 AND #2 AND #3 AND ([embase]/lim AND 'human'/de)



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>





# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018070.R2
Article Type:	Research
Date Submitted by the Author:	01-May-2018
Complete List of Authors:	Huang, Chengzhi; Shantou University, Medical College; Guangdong General Hospital, Department of General Hospital Yu, Mengya; Guangdong General Hospital, Department of General Hospital; Southern Medical University Yao, Xueqing; Guangdong General Hospital; Shantou University, Medical College
<b>Primary Subject Heading</b>:	Genetics and genomics
Secondary Subject Heading:	Gastroenterology and hepatology, Oncology, Pathology, Surgery
Keywords:	microRNA-17, Cancer, Outcome, Prognosis, Meta-analysis

SCHOLARONE™  
Manuscripts

## MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis

Chengzhi Huang<sup>1,2</sup>, Mengya Yu<sup>2,3</sup>, Xueqing Yao<sup>1,2,3#</sup>

1 Medical College, Shantou University, Shantou, Guangdong, China.

2 Department of General Surgery, Guangdong General Hospital (Guangdong Academy of Medical Sciences),  
Guangzhou, Guangdong, China.

3 Southern Medical University, Guangzhou, Guangdong, China.

# To whom correspondence should be addressed:

Xueqing Yao

No.106 Zhongshaner Road, Guangzhou, Guangdong, China, 510000.

Phone: 020-83827812

Fax: 020-83827812

Email: [yjb9211@21cn.com](mailto:yjb9211@21cn.com)

## Abstract

**Objective** Although the role of microRNA-17(miR-17) has been identified as a tumor biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyze and summarize the relationship between the miR-17 status and clinical outcome in a variety of human cancers.

**Design** Systematic review and meta-analysis.

**Data sources** PubMed, Web of Science, and Embase from the first year of records through May 15th, 2017

**Outcomes** The patients' survival results were pooled, and pooled hazard ratio (HR) with 95% confidential intervals were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma, and colon cancer. Heterogeneity, publication bias, and subgroup analysis were also conducted.

**Results** A total of 1096 patients were included in this meta-analysis from 12 articles. The results indicated that the increased expression of miR-17 played an unfavorable role in overall survival (OS) in various human carcinomas with the HR of 1.342taking into account the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38), detection method (qRT-PCR HR=1.40 and in situ hybridization, ISH HR=2.59), and detection sample (tissue HR=1.45 and serum HR=1.32) were significant with  $p < 0.05$ . For the analysis of disease-free survival and recurrence-free survival, the increased expression of miR-17 was associated with unfavorable prognosis (HR=1.40).

**Conclusions** miR-17 may be a useful biomarker in predicting the clinical outcome of human cancers, but due to the limitations of the current studies, further verification of the role of miR-17 in human malignancies is urgently needed.

**Keywords** microRNA-17; Cancer; Outcome; Prognosis; Meta-analysis.

## Strengths and limitations of the study

1. This is the first meta-analysis that summarized and reported the microRNA-17 as a novel potential cancer prognostic biomarker in the clinical field.
2. We used strict, broad search strategy of the internet databases to minimize any potential publication bias.
3. We conducted the subgroup analysis and found that the up-regulated expression of microRNA-17 may imply poor clinical outcome in digestive system cancers.
4. The major limitation of our meta-analysis is the inclusion of a limited number of studies carried out on Western populations decreasing the applicability of our results among other ethnicities. MicroRNA-17

1 detection is not routine clinical practice, and the prognostic value of microRNA-17 remains controversial. In  
2 the future, additional clinical trials are needed to verify the prognostic significance of microRNA 17.  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction

Despite significant advances in clinical research over the past few decades, cancer is still a key health burden and a leading cause of death worldwide. In the year 2017, it is estimated that 1,688,780 patients were diagnosed with cancers with 600,920 cancer deaths in the United States<sup>1</sup>. Due to the advanced screening methods and adjuvant systemic therapies for newly diagnosed cases, the mortality rate for cancers is declining in the developed countries<sup>2</sup>, whereas the clinical outcome of cancers in the developing countries is still poor<sup>3,4</sup>.

There are several independent factors for identifying and evaluating the clinical outcome of human cancers, including tumor size, histological grade, age of the patients, and metastasis to lymph nodes<sup>5-8</sup>. Tissue- and serum-based tumor biomarkers are widely used to predict the prognosis of neoplasms. However, these techniques are far from satisfactory due to the low specificity and sensitivity<sup>9-11</sup>. Thus, a less-invasive and more accurate biomarker would be of great value for the prognosis of human tumors.

The discovery of microRNAs (miRNAs) provided an innovative method for the prognosis of cancers by a less-invasive detection method<sup>12</sup>. miRNAs, a class of endogenous non-coding single-stranded RNAs with the length of 18-25 nucleotides, act as regulators of gene expression by pairing with the complementary nucleotides in the 3'-untranslated regions (3'-UTR) of their target mRNAs. miRNAs may act as regulators of cell growth, proliferation, differentiation and apoptosis<sup>13</sup>. Because of these fundamental activities, numerous studies have shown that miRNAs function as tumor suppressors or oncogenes. It has also been reported that some miRNAs are differentially expressed between tumor and non-tumor tissues, and the abnormal expression of tumor-associated miRNAs can be detected in patient's blood, cancerous tissue and fecal samples<sup>14,15</sup>. Recent studies have demonstrated that aberrantly expressed miRNAs, especially those acting as tumor suppressors or oncogenes, are related to cancer development, progression, and patients' response to therapy<sup>16-18</sup>. Therefore, miRNAs can be considered as useful prognostic biomarkers for various human cancers.

One such example is of miR-17 that is aberrantly expressed in cancer patients<sup>19-21</sup>. The miR-17 family, which includes six members, is one of the most extensively studied miRNA clusters<sup>22</sup>. These miRNAs are located within an 800 base-pair region of human chromosome 13, play an essential role in the development of the heart, lung, and human immune system<sup>23</sup>. Recent studies have found that miR-17 may play a critical role in the development of human cancers.<sup>24,25</sup> Increased expression of miR-17 promotes the metastasis of lung and pancreatic cancers, suggesting its role as an oncogene<sup>26,27</sup>. However, other studies have reported that miR-17 inhibits tumor cell invasion and metastasis in breast cancer<sup>28</sup>. In all, the role of miR-17 in cancer development as well as the exact mechanism are not yet clearly described. According to the miRBase (<http://www.mirbase.org>), miR-17 includes two members, miR-17-5p and miR-17-3p which are located in the sequence of miR-17 with a stem-loop structure. As a result, the detection of miR-17-5p, miR-17-3p has the same effect as detecting miR-17<sup>29-33</sup>.

Several published results indicate that the higher expression of the miR-17 is indicative of poor prognosis in cancer patients<sup>26 27 34-43</sup>. However, several confounding factors, including race, detection method, and tumor site, may affect the observations making the relationship between aberrant expression of miR-17 and the clinical outcome of cancer patients inconsistent. We, therefore, conducted a meta-analysis of available studies to evaluate the clinical utility of miR-17 as a novel cancer prognostic indicator.

## Material and Methods

### Data Source and Search Strategy

The following online electronic databases were used for the literature search: PubMed, Web of Science, and Embase. The search period was up to May 15th, 2017. Key search words used were: (1) prognosis OR prognostic OR survival OR outcome OR mortality; (2) cancer OR tumor OR tumour OR carcinoma OR neoplasm; (3) miR-17 OR microRNA-17 OR hsa-mir-17. Details are listed in the Supplementary Table 1. Additionally, we also searched the references and relevant published articles via Google Scholar.

### Inclusion and Exclusion Criteria

The inclusion criteria of the articles were: (1) the cancers were diagnosed by the histological examination or any other accepted standard; (2) miR-17 was studied in human cancers; (3) the expression of miR-17 and the clinical outcome of patients were included in the research; and (4) reports with survival outcome and the data analyzed hazard ratio (HR) with 95% confidence interval (95% CI) and HR with a *P*-value.

The exclusion criteria were: (1) duplicate publications; (2) articles focused on other genes; (3) case reports, reviews, letters, and animal trials; (4) unqualified or insufficient data; (5) HR, 95% CI and *P*-value were not provided or could not be calculated and (6) articles concentrated on the polymorphisms or methylation patterns of miRNAs.

Questions of suitability of articles to be included were examined and discussed by the authors after reviewing the abstract and full text manuscript. The final decision was made by the academic committee.

### Data extraction and quality assessment

All included studies were decided by the two investigators (Huang and Yao) independently based on titles and abstracts. Full-text of the articles was required if the articles were potentially suitable for the meta-analysis. Furthermore, the literature search was performed again in the excluded articles to avoid missing any article potentially relevant for the study. The original authors of the articles were contacted if any supplementary data were needed. Any disagreement was resolved by the two authors (Huang and Yao). The extracted details of the articles were as follows: (1) publication information: the name of the authors, publication area, and publication year; (2) patient's characteristics: diseases, stage of the disease, RNA detection method, type of tissue sample

and follow-up years; (3) the measurement of miR-17 measurement and its cut-off value and (4) HR of miR-17 for overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS), as well as their 95% CI and *P*-values. The HRs and their 95% CI were extracted from the original articles or via e-mails from the authors. If not, we calculated HR and 95% CI using the data of observed deaths, cancer recurrences, or the original data provided by the authors. All calculations mentioned above were based on the methods provided by Parmar, M. K. et al.<sup>44</sup>. The quality of the included articles was assessed based on a systematic review checklist of the Dutch Cochrane Centre proposed by MOOSE<sup>45</sup>.

## Statistical Analysis

The test of heterogeneity of pooled HRs was carried out by using Cochran's *Q*-test and Higgins *I*<sup>2</sup> statistic. A *P*-value of < 0.05 or *I*<sup>2</sup> > 50% was considered as statistically significant. The 95%CI of *I*<sup>2</sup> was calculated by the method introduced by Hedges et al<sup>46</sup>. If heterogeneity existed, the random effects model was performed among the included studies; otherwise, the fixed effects model was selected. *I*<sup>2</sup> value ranged from 0% to 100%. All *P*-values were two-sided.

HR >1 presents of up-regulated expression of miR-17 indicated poor prognosis in patients, and HR <1 suggested a better prognosis. Publication bias was evaluated by the Begg's test and Egger's test<sup>47 48</sup>. If the publication bias did exist, the trim and fill method introduced by Duval and the Tweedit's was used to adjust the results<sup>49</sup>. The STATA software Version 14.0 (StataCorp LP, College Station, TX, USA) was used in all of the statistical analyses.

## Study registration

The systematic review and meta-analysis is registered in PROSPERO (No. CRD42017065749).

## Patients and Public Involvement Statement

The patients or public were not involved in the study.

## Results

### Literature selection

We started with 405 articles associated with miR-17 and cancer prognosis was identified from online database searches. After removing the replicate records, 304 miR-17-related articles were left. The first screening based on the species, article type, and language eliminated 210 citations from the analysis. Subsequently, the remaining 104 studies were carefully assessed by reviewing the abstract and full text of each article. After that, 89 articles were excluded from the study because they were unrelated to miR-17 expression levels or because of the lack of survival statistics such as HRs, 95% CI, or *P*-value. Finally, 15 studies, which



investigated the potential relationship between miR-17 expression and prognosis of human cancers, remained for further detailed screening and data-extraction. Three of the studies that explained the relationship between miR-17 expression and the clinical outcome of cancer had to be removed because the authors did not provide the exact HR value, or the value cannot be calculated from the data. Thus, 12 articles (12 studies)<sup>26 27 34-43</sup> were included in this meta-analysis. (Figure 1)

### Characteristics of selected studies

All 12 studies included in the meta-analysis were retrospective studies published between 2010 and 2016<sup>26 27 34-43</sup>. Patient's OS was reported in all 12 studies, and three studies also examined the DFS or RFS. The type of the cancers included gastrointestinal cancers (colorectal cancer, gastric cancer), lung cancer, pancreatic cancer, hepatocellular cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and esophageal squamous cell carcinoma. Total of 1096 patients with various types of cancers were from People's Republic of China, Japan, Spain, and Brazil. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression of miR-17 in 12 studies, and one study used the in-situ hybridization (ISH). All studies used tissue and serum samples as the source of the miR-17. The majority (10 of 12) of the HRs reported in the present analysis were included in the multivariate analysis. The remaining two HRs could be estimated by Kaplan-Meier analysis and relative risk (RR) values. Most of the studies have the follow-up research for at least 38 months. The clinical characteristics of the studies included in this article are summarized in Table 1(A summary table of the meta-analysis).

Study	Year	Country	Diseases	Case Number	Stage	Sample	Assay	Cut-off value	HR	Follow-up (months)	Type of miR-17 detection
Chen et al	2012	China	HCC	120	I-IV	Tissue	qRT-PCR	Median	RR	46	miR-17-5p
Qun et al	2013	China	Lung Cancer	221	I-IV	Tissue	qRT-PCR	Median	Given	50	miR-17
Li et al	2014	China	Osteosarcoma	117	I-III	Tissue	qRT-PCR	Median	Given	44	miR-17
Lu et al	2012	China	Glioma	108	I-IV	Tissue	qRT-PCR	Mean	RR	60	miR-17
Xi et al	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	Given	Up to 13 years	miR-17
Yu et al	2012	China	Colon Cancer	48	I-IV	Tissue	qRT-PCR	Median	Given	5-66	miR-17
Manuel et al	2011	Spain	Gastrointestinal Cancer	38	I-IV	Tissue	qRT-PCR	Mean	Given	38	miR-17
Robaina et al	2016	Brazil	Burkitt lymphoma	41	I-IV	Tissue	ISH	Median	Given	69	miR-17
Xu et al	2014	China	Esophageal Squamous Cell Carcinoma	105	I-IV	Tissue	qRT-PCR	Mean	Given	52	miR-17
Jun et al	2010	Japan	Pancreatic Cancer	80	I-IV	Tissue	qRT-PCR	Median	Given	60	miR-17-5p
Wang et al	2011	China	Gastric Cancer	65	I-IV	Serum	qRT-PCR	Median	Given	36	miR-17-5p
Zheng et al	2013	China	HCC	96	I-IV	Serum	qRT-PCR	Median	Given	NG	miR-17-5p

Table 1(A summary table of the meta-analysis).

## Association between miR-17 and OS

Due to low heterogeneity, fixed effects model was used to calculate and analyze the pooled HR value. High expression level of miR-17 was associated with the poor OS in patients with diverse cancers. The statistical power of  $Q$ -test is low when there are limited studies included in the meta-analysis. We, therefore, conducted random effect analysis on the OS (HR=1.45, 95%CI=1.29-1.63,  $P<0.001$ ), which was not significantly different compared to the analysis of fixed effect model. Details of the meta-analysis are systematically summarized in the Figure 2.

Subgroup	Number of studies	Heterogeneity		pooled HR (95% CI)	P-value
		$I^2$ (95%CI)	P-value		
<b>Total</b>	12	38.2% (0%-68.7%)	0.086	1.42(1.30-1.55)	<0.001
<b>Ethnic subtotal</b>					
Caucasian	2	71.6% (0%-93.6%)	0.06	1.48(1.21-1.81)	<0.001
Asian	10	36.1% (0%-69.5%)	0.12	1.40(1.27-1.55)	<0.001
<b>Disease subtotal</b>					
Digestive system	7	34.8% (0%-72.4%)	0.163	1.36(1.22-1.51)	<0.001
Respiratory system	1	NA	NA	1.28(1.02-1.61)	0.036
Blood system	2	0	0.713	2.38(1.56-3.63)	<0.001
Glioma	1	NA	NA	1.61(1.19-2.18)	0.002
Osteosarcoma	1	NA	NA	1.61(1.19-2.18)	<0.001
<b>Detected method subtotal</b>					
qRT-PCR	11	29.0% (0%-65.0%)	0.169	1.40(1.28-1.53)	<0.001
ISH	1	NA	NA	2.59(1.39-4.81)	0.003
<b>Detected Sample subtotal</b>					
Tissue	10	46.2% (0%-74.1%)	0.053	1.45(1.31-1.61)	<0.001
Serum	2	0	0.662	1.32(1.10-1.57)	0.002
<b>Detection of miR-17 subtotal</b>					
miR-17	8	60.1% (13.2%-81.7%)	0.057	1.29(1.11-1.49)	<0.001
miR-17-5p	4	7.5% (0%-43.4%)	0.372	1.50(1.34-1.67)	0.001

Table 2(Subgroup analysis).

To demonstrate the predictive role of miR-17, subgroups analysis was conducted based on patients' ethnicity, cancer type, methods identifying miRNAs and type of tissue samples. Clinical association between miR-17 and OS was found in the Asian and Caucasian patients(Figure 3A). The association was also significant in other subgroups, including digestive system cancers and blood cancers(Figure 3B), qRT-PCR detection method(Figure 3C), and tissue and serum samples(Figure 3D). miR-17 includes two members, miR-17-5p and miR-17-3p which are located in the sequence of miR-17 with a stem-loop structure. Therefore, analysis of miR-17-5p or miR-17-3p afforded the same effect (or result) as miR-17. To clarify the heterogeneity, we conducted a subgroup analysis concerning the detection method of miR-17 and found that the clinical value was also significant in miR-17 group and

miR-17-5p group. There was no significant difference between the two groups (Figure 3E), implying that same effect existed when detecting miR-17 and miR-17-5p. Details of the subgroup analysis are listed in the Table 2(Subgroup analysis).

### Correlation between miR-17 and DFS and RFS

A total of 3 studies<sup>37 38 41</sup> were included in the analysis of DFS and RFS. The analyses revealed a predictive role of increased expression of miR-17 for the prognosis of cancer patients (pooled HR= 1.40, 95% CI=1.23-1.60,  $P<0.001$ ) as determined by the fix-effect model ( $I^2=15.8\%$ ,  $P=0.305$ ) (Figure 4).

### Publication bias

We used Begg's funnel plot and Egger's test to assess the possible publication bias of the included studies<sup>47 48</sup>. In the analysis of relationship between miR-17 and the OS, the  $P$ -values of Egger's test and Begg's test were 0.014 and 0.011, respectively. The funnel plot and Egger's plot are displayed in Figure 5A and Figure 5B. Both Begg's test and Egger's test implied a publication bias, thus the trim and fill method was performed to make pooled HR more reliable<sup>49</sup>. The altered HR was 1.34, 95% CI=1.24-1.46,  $P<0.001$ , which was not significantly different from the pooled HR (Supplementary Figure 1).

### Discussion

Previous studies have shown that miRNAs have a distinct expression profile in cancerous tissues which can be detected by qRT-PCR in frozen, formalin-fixed, and paraffin-embedded tissues and in serum samples. Recently, miRNAs, serving as tumor suppressors or oncogenes, have been shown to play important roles in the evolution and progression of cancers. miRNAs are involved in a variety of crucial cellular pathways such as angiogenesis, innate and adaptive immune responses, cellular proliferation, invasion, and metastasis.<sup>12 16</sup> Several studies have reported the potential use of miRNAs as tumor biomarkers for detecting tumor occurrence, development, and prognosis. Unfortunately, effective diagnosis techniques and prognosis indicators of cancer have not been found. Developing a novel less-invasive detection method with higher accuracy for cancer prognosis is of great significance in evaluating cancer progression as well as monitoring patients' therapeutic response.

Over the last couple of decades, numerous studies have uncovered the involvement of miRNAs in the pathogenesis of cancer. Since miRNAs can be obtained noninvasively from the serum, urine, and fecal samples, their utility as diagnostic and prognostic biomarkers in cancer and other diseases has been extensively explored. It has been reported that miRNA could be detected with higher accuracy than traditional cancer biomarkers in predicting the clinical outcome of the human colon cancers<sup>50</sup>. However, adequate evidence is still lacking for the utility of miRNAs as cancer biomarkers in clinical practice.

miR-17, a widely-studied miRNA, is aberrantly expressed in different kinds of cancers, such as glioma<sup>51</sup>, esophageal and oral squamous cell carcinomas<sup>36,52</sup>, pancreatic cancer<sup>26</sup>, gastrointestinal cancers<sup>39</sup>, osteosarcoma<sup>53</sup> and Burkitt lymphoma<sup>38</sup>, and is significantly related to the clinical outcome of cancers. Our meta-analysis indicated that the elevated miR-17 expression is significantly associated with poor OS (HR=1.42) in patients with various types of carcinomas. The analysis using the Cochran's *Q*-test and Higgins *I*<sup>2</sup> test implied low heterogeneity. As limited number of studies were included in the meta-analysis, the *Q*-test had inadequate statistical power. We, therefore, applied the fixed effects model to calculate and analyze the pooled HR value. We also conducted random effect analysis on the OS, which was not significantly different when compared to analysis of fixed effect model (Figure 2). In the subgroup analysis, we found that the potential heterogeneity may have originated from the Caucasian group in the study conducted by Robaina et al.<sup>38</sup>. Unlike the commonly used RT-PCR, ISH technique was used to detect miR-17. Other factors contributing to the heterogeneity may include the limited number of patients (n=41) recruited in the study. However, both studies from Spain and Brazil recruited population of Caucasians decreasing the heterogeneity.

As the Begg's test and the Egger's test implied publication bias, we used the Trim and Fill method to obtain a more reliable pooled HR. We found that the adjusted HR was not significantly different from the pooled HR. In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the Caucasian and Asian groups, the qRT-PCR group and the tissue and serum sample groups. Furthermore, the increased expression of miR-17 indicated poor DFS and RFS in HCC and gastrointestinal cancers. Several investigators have explored the functional roles of miR-17 and its involvement in human cancers. Yang et al. found that the miRNA-17 was overexpressed in the HCC tissue, and promoted the phosphorylation of heat shock protein 27 (HSP27). The phosphorylated HSP27 then enhanced the migration of the HCC cells implying a significant role of miRNA-17 in the progression of HCC<sup>54</sup>. Wang et al. reported that the up-regulated expression of miRNA-17-5p promoted cancer cells proliferation and inhibited apoptosis by post-transcriptional modulation of mRNA p21 and tumor protein p53-induced nuclear protein 1 (TP53INP1)<sup>55</sup>. In the study by Ma et al. overexpression of miRNA-17 promoted cancer cells progression by targeting P130<sup>56</sup>. Yan et al. found over-expression of the miR-17-5p in pancreatic cancer. The miR-17-5p inhibitor promoted the expression of Bim protein by targeting the 3'-untranslated regions of its mRNA and negatively regulating at the posttranscriptional level. Therefore, the authors suggested that the miR-17-5p inhibitor may be a novel therapeutic approach for pancreatic cancer<sup>57</sup>. Together with our meta-analysis, these findings suggest that the detection of tissue or serum miR-17 expression may be a useful prognostic biomarker in patients with HCC, pancreatic cancer, and gastrointestinal cancers.

There are potential limitations of this study. The literature searches using authentic and widely used data bases found studies performed predominantly on Asian populations not encompassing sufficient numbers of other populations such as Caucasians. Our results of miR-17 as a potential biomarker may, therefore, not be applicable to other populations. The pooled HR values were also not sufficiently strong. Furthermore, the

1 relatively limited sample size of 1031 patients weakened the statistical significance of the prognostic potential  
2 of miR-17 expression levels.  
3  
4

## 5 **Conclusions**

6 In summary, our meta-analysis suggested that miR-17 is a potential biomarker in various types of cancers.  
7  
8 However, further multi-center clinical trials with larger sample size and prospective studies including  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 16 **Acknowledgments**

18 We thank the grants from Guangdong Science and Technology Department, China.

## 21 **Contributors**

23 Chengzhi Huang and Mengya Yu conceived the study. Chengzhi Huang and Xueqing Yao performed the  
24 data extraction and analysed the data. Chengzhi Huang and Mengya Yu wrote the paper. All authors had full  
25 access to all of the data and approved the final version of manuscript.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 30 **Disclosure of conflicts**

32 The authors report no conflicts of interest in this work.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 36 **Data Sharing Statement**

38 No additional data are available  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 41 **Funding**

43 The article is funded by Guangdong Science and Technology Department, China. (No.2014A020212636).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 47 **Ethics approval**

49 The study does not include human participants or animals.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 52 **Patients and Public Involvement Statement**

54 The patients or public were not involved in the study.  
55  
56  
57  
58  
59  
60

## 58 **Reference**

- 1 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67(1):7-30. doi:  
2 10.3322/caac.21387
- 3 2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin*  
4 2015;65(2):87-108. doi: 10.3322/caac.21262
- 5 3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*  
6 2016;66(2):115-32. doi: 10.3322/caac.21338
- 7 4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer*  
8 *J Clin* 2012;62(4):220-41. doi: 10.3322/caac.21149
- 9 5. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. *Cancer*  
10 1969;24(5):1071-80.
- 11 6. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409  
12 cases of which 359 have been followed for 15 years. *Br J Cancer* 1957;11(3):359-77.
- 13 7. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in  
14 breast cancer: population based study. *BMJ* 2000;320(7233):474-8.
- 15 8. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the  
16 prognosis of patients with primary breast cancer. An NSABP update. *Cancer*  
17 1983;52(9):1551-7.
- 18 9. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of  
19 existing programmes. *Gut* 2015;64(10):1637-49. doi: 10.1136/gutjnl-2014-309086
- 20 10. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal  
21 cancer. *Cochrane Database Syst Rev* 2015(12):CD011134. doi:  
22 10.1002/14651858.CD011134.pub2
- 23 11. Sun W, Liu Y, Shou D, et al. AFP (alpha fetoprotein): who are you in gastrology? *Cancer Lett*  
24 2015;357(1):43-6. doi: 10.1016/j.canlet.2014.11.018
- 25 12. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis.  
26 *Cancer Res* 2007;67(10):4553-5. doi: 10.1158/0008-5472.CAN-07-0563
- 27 13. Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by  
28 miRNAs and siRNAs. *Genes Dev* 2006;20(5):515-24. doi: 10.1101/gad.1399806
- 29 14. Rokkas T, Kothonas F, Rokka A, et al. The role of circulating microRNAs as novel biomarkers in  
30 diagnosing colorectal cancer: a meta-analysis. *Eur J Gastroenterol Hepatol* 2015;27(7):819-25.  
31 doi: 10.1097/MEG.0000000000000363
- 32 15. Yang X, Zhong J, Ji Y, et al. The expression and clinical significance of microRNAs in colorectal  
33 cancer detecting. *Tumour Biol* 2015;36(4):2675-84. doi: 10.1007/s13277-014-2890-0
- 34 16. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. miRNA biogenesis:

- 1 biological impact in the development of cancer. *Cancer Biol Ther* 2014;15(11):1444-55. doi:  
2 10.4161/15384047.2014.955442  
3
- 4 17. Cho WC. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and  
5 Prognosis. *Front Genet* 2011;2:7. doi: 10.3389/fgene.2011.00007  
6
- 7 18. Avery-Kiejda KA, Braye SG, Mathe A, et al. Decreased expression of key tumour suppressor  
8 microRNAs is associated with lymph node metastases in triple negative breast cancer. *BMC*  
9 *Cancer* 2014;14:51. doi: 10.1186/1471-2407-14-51  
10
- 11 19. Liang Y, Yang W, Zhu Y, et al. Prognostic role of microRNA-203 in various carcinomas: evidence  
12 from a meta-analysis involving 13 studies. *Springerplus* 2016;5(1):1538. doi:  
13 10.1186/s40064-016-3225-y  
14
- 15 20. Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microRNA-21 in gastric cancer: a meta-analysis.  
16 *Med Sci Monit* 2014;20:1668-74. doi: 10.12659/MSM.892096  
17
- 18 21. Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association  
19 with disease characteristics and patient survival. *J Int Med Res* 2013;41(3):596-602. doi:  
20 10.1177/0300060513485856  
21
- 22 22. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics,  
23 genetics, functions and increasingly important and numerous roles in health and disease. *Cell*  
24 *Death Differ* 2013;20(12):1603-14. doi: 10.1038/cdd.2013.125  
25
- 26 23. Mendell JT. miRiad Roles for the miR-17-92 Cluster in Development and Disease. *Cell*  
27 2008;133(2):217-22.  
28
- 29 24. Wang Q, Li YC, Wang J, et al. miR-17-92 cluster accelerates adipocyte differentiation by  
30 negatively regulating tumor-suppressor Rb2/p130. *Proceedings of the National Academy of*  
31 *Sciences* 2008;105(8):2889.  
32
- 33 25. Ottman R, Levy J, Grizzle WE, et al. The other face of miR-17-92a cluster, exhibiting tumor  
34 suppressor effects in prostate cancer. *Oncotarget* 2016;7(45):73739.  
35
- 36 26. Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer,  
37 associated with a poor prognosis, and involved in cancer cell proliferation and invasion. *Cancer*  
38 *Biology & Therapy* 2010;10(8):748.  
39
- 40 27. Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. *Medical*  
41 *Oncology* 2013;30(1) doi: 10.1007/s12032-012-0353-2  
42
- 43 28. Yu Z, Koprowski H. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast  
44 cancer by heterotypic signaling. *Proceedings of the National Academy of Sciences of the*  
45 *United States of America* 2010;107(18):8231.  
46
- 47 29. Griffiths-Jones S. The microRNA Registry. 2004  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1 30. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep  
2 sequencing data. *Nucleic Acids Research* 2014;42(Database issue):68-73.
- 3
- 4 31. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing  
5 data. *Nucleic Acids Research* 2011;39(Database issue):D152-7.
- 6
- 7 32. Griffiths-Jones S, Grocock RJ, Dongen SV, et al. miRBase: microRNA sequences, targets and gene  
8 nomenclature. *Nucleic Acids Research* 2006;34(suppl 1):140-4.
- 9
- 10 33. Griffiths-Jones S, Saini HK, Van DS, et al. miRBase: tools for microRNA genomics. *Nucleic Acids*  
11 *Research* 2008;36(Database issue):154-8.
- 12
- 13 34. Zheng JJ, Dong PH, Gao SM, et al. High Expression of Serum miR-17-5p Associated with Poor  
14 Prognosis in Patients with Hepatocellular Carcinoma. *Hepato-Gastroenterology*  
15 2013;60(123):549-52. doi: 10.5754/hge12754
- 16
- 17 35. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts poor prognosis in  
18 human glioma. *Journal of biomedicine & biotechnology* 2012;2012:970761. doi:  
19 10.1155/2012/970761 [published Online First: 2012/12/12]
- 20
- 21 36. Xu XL, Jiang YH, Feng JG, et al. MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic  
22 indicators in esophageal squamous cell carcinoma. *Annals of Thoracic Surgery*  
23 2014;97(3):1037-45.
- 24
- 25 37. Chen L, Jiang M, Yuan W, et al. miR-17-5p as a novel prognostic marker for hepatocellular  
26 carcinoma. *Journal of investigative surgery : the official journal of the Academy of Surgical*  
27 *Research* 2012;25(3):156-61. doi: 10.3109/08941939.2011.618523 [published Online First:  
28 2012/05/16]
- 29
- 30 38. Robaina MC, Faccion RS, Mazzocchi L, et al. miR-17-92 cluster components analysis in Burkitt  
31 lymphoma: overexpression of miR-17 is associated with poor prognosis. *Annals of Hematology*  
32 2016;95(6):881-91.
- 33
- 34 39. Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impact of disseminated tumor cells and  
35 microRNA-17-92 cluster deregulation in gastrointestinal cancer. *International Journal of*  
36 *Oncology* 2011;39(5):1253.
- 37
- 38 40. Yu G, Tang JQ, Tian ML, et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon  
39 cancer. *Journal of Surgical Oncology* 2012;106(3):232-37. doi: 10.1002/jso.22138
- 40
- 41 41. Li X, Yang H, Tian Q, et al. Upregulation of microRNA-17-92 cluster associates with tumor  
42 progression and prognosis in osteosarcoma. *Neoplasma* 2014;61(4):453-60. doi:  
43 10.4149/neo\_2014\_056
- 44
- 45 42. Xi YF, Li J, Zhang P, et al. Upregulation of miRNA-17 and miRNA-19 is associated with  
46 unfavorable prognosis in patients with T-cell lymphoblastic lymphoma. *Experimental and*  
47 *Molecular Medicine* 2014;46(11):1000-1006. doi: 10.1038/emmm.2014.111
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



- 1 *Molecular Pathology* 2015;99(2):297-302. doi: 10.1016/j.yexmp.2015.07.012
- 2 43. Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric  
3 cancer. *Mol Med Rep* 2012;5(6):1514-20. doi: 10.3892/mmr.2012.828
- 4 44. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the  
5 published literature for survival endpoints. *Stat Med* 1998;17(24):2815-34.
- 6 45. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a  
7 proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)  
8 group. *JAMA* 2000;283(15):2008-12.
- 9 46. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. *Psychological Methods*  
10 2001;6(3):203-17.
- 11 47. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test.  
12 *BMJ* 1997;315(7129):: 629-34.
- 13 48. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  
14 *Biometrics* 1994;50(4):1088-101.
- 15 49. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for  
16 publication bias in meta-analysis. *Biometrics* 2000;56(2):455-63.
- 17 50. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA Expression Profiles Associated With Prognosis  
18 and Therapeutic Outcome in Colon Adenocarcinoma. *Jama* 2008;299(4):425-36.
- 19 51. Lu S, Wang S, Geng S, et al. Increased expression of microRNA-17 predicts poor prognosis in  
20 human glioma. *Biomed Research International* 2012;2012(2012):970761.
- 21 52. Chang CC, Yang YJ, Li YJ, et al. MicroRNA-17/20a functions to inhibit cell migration and can be  
22 used a prognostic marker in oral squamous cell carcinoma. *Oral Oncology* 2013;49(9):923-31.
- 23 53. Li S, Gao Y, Wang Y, et al. Serum microRNA-17 functions as a prognostic biomarker in  
24 osteosarcoma. *Oncology Letters* 2016;12(6):4905-10.
- 25 54. Yang F, Yin Y, Wang F, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma  
26 cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway.  
27 *Hepatology* 2010;51(5):1614-23.
- 28 55. Wang M, Gu H, Qian H, et al. miR-17-5p/20a are important markers for gastric cancer and murine  
29 double minute 2 participates in their functional regulation. *European Journal of Cancer*  
30 2013;49(8):2010.
- 31 56. Ma Y, Zhang P, Wang F, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal  
32 cancer progression by repressing its target gene P130. *Nature Communications*  
33 2012;3(4):1291.
- 34 57. Yan HJ, Liu WS, Sun WH, et al. miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 upregulating Bim expression in pancreatic cancer cells. *Digestive Diseases and Sciences*  
2 2012;57(12):3160-67.  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Figure and table legends

Figure 1 Flow diagram of the studies selection phase

Figure 2 Forest plot of meta-analysis of overall survival in association with miR-17 expression.

Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression.

(A) Forest plots of the merged analyses of OS in different ethnic groups. Squares and lines correspond to the study-specific HRs and 95% CIs, respectively. The area of the squares represents the weight, and the diamonds represent the summary of HRs and 95% CIs.

(B) Forest plots of the merged analyses of OS in different diseases groups.

(C) Forest plots of the merged analyses of OS in different RNA detection methods groups.

(D) Forest plots of the merged analyses of OS in different sample groups.

(E) Forest plots of the merged analyses of OS in the detection method of miR-17.

Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in association with miR-17 expression.

Figure 5

(A) Funnel plot of merged analysis of OS comparing high or low expression of miR-17.

(B) Egger's plot of merged analysis of OS comparing high or low expression of miR-17.

Table 1. A summary table of the meta-analysis.

Abbreviations: miR-17, microRNA-17; HCC, hepatocellular carcinoma; ISH, in situ hybridization; qRT-PCR, quantitative real-time polymerase chain reaction; RR, risk ratio; OS, overall survival; DFS, disease-free survival; NG, not given.

Table 2 Subgroup analysis.

Abbreviations: miR-17, microRNA-17; miR-17-5p, microRNA-17-5p; qRT-PCR, quantitative real-time polymerase chain reaction; ISH, in situ hybridization; NA, not available.

Supplementary Table 1 The search strategy of online databases

Supplementary Figure 1 Funnel plot of adjusted pooled HRs after the analysis of the Trim and Fill method.




Figure 1 Flow diagram of the studies selection phase

193x206mm (300 x 300 DPI)




Figure 2 Forest plots of meta-analysis of overall survival in association with miR-17 expression.

210x161mm (300 x 300 DPI)




Figure 3 Forest plots of subgroup meta-analysis of OS in association with miR-17 expression. (A) Forest plots of the merged analyses of OS in different ethnic groups. Squares and lines correspond to the study-specific HRs and 95% CIs, respectively. The area of the squares represents the weight, and the diamonds represent the summary of HRs and 95% CIs. (B) Forest plots of the merged analyses of OS in different disease groups. (C) Forest plots of the merged analyses of OS in different RNA detection methods groups. (D) Forest plots of the merged analyses of OS in different sample groups. (E) Forest plots of the merged analyses of OS in the detection method of miR-17.

233x299mm (300 x 300 DPI)




Figure 4 Forest plot of disease-free survival(DFS) and recurrence-free survival (RFS) in association with miR-17 expression.

190x124mm (300 x 300 DPI)




Figure 5  
 (A) Funnel plot of merged analysis of OS comparing high or low expression of miR-17.  
 (B) Egger's plot of merged analysis of OS comparing high or low expression of miR-17.


209x81mm (300 x 300 DPI)

Peer review only



# Filled funnel plot with pseudo 95% confidence limits

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33



For peer review only. <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

18. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

**Supplementary Table 1 The search strategy of online databases**

Databases	Search method
Pubmed	("MIRN17 microRNA, human" [Supplementary Concept] AND "Neoplasms"[Mesh] AND "Prognosis"[Mesh])
Web of Science	
1	TS=(cancer OR neoplas* OR carcinom* OR tumo*)
2	TS=(prognosis OR prognostic OR survival OR outcome OR mortality)
3	TS=(miR-17 OR microRNA-17 OR hsa-mir-17)
4	#1 AND #2 AND #3
Embase	
1	miR-17 OR microRNA-17 OR hsa-mir-17
2	cancer OR neoplas* OR carcinom* OR tumo*
3	prognosis OR prognostic OR survival OR outcome OR mortality
4	#1 AND #2 AND #3 AND ([embase]/lim AND 'human'/de)



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

## Correction: *MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis*

Huang C, Yu M, Yao X. MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis. *BMJ Open* 2018;8:e018070. doi:10.1136/bmjopen-2017-018070.

This article was previously published with some errors.

In the table 1, table 2 and figure 1, Robaina *et al.* conducted the study of miR-17 by the method of qRT-PCR instead of ISH as we described in the paper (citation number 38). Secondly, the term Caucasian is not applied in Brazilian for ethnicity classification. The authors would therefore like to use the term non-Asian for describing the studies conducted in the Spain and Brazil. The issue did not affect the main result and the conclusion of the study. Below is the updated table 2 and figure 1.


Table 1 A summary table of the meta-analysis

Study	Year	Country	Diseases	Case Number	Stage	Sample	Assay	Cut-off value	HR	Follow-up (months)	Type of miR-17 detection
Chen <i>et al</i>	2012	China	HCC	120	I-IV	Tissue	qRT-PCR	Median	RR	46	miR-17-5p
Qun <i>et al</i>	2013	China	Lung Cancer	221	I-IV	Tissue	qRT-PCR	Median	Given	50	miR-17
Li <i>et al</i>	2014	China	Osteosarcoma	117	I-III	Tissue	qRT-PCR	Median	Given	44	miR-17
Lu <i>et al</i>	2012	China	Glioma	108	I-IV	Tissue	qRT-PCR	Mean	RR	60	miR-17
Xi <i>et al</i>	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	Given	Up to 13 years	miR-17
Yu <i>et al</i>	2012	China	Colon Cancer	48	I-IV	Tissue	qRT-PCR	Median	Given	5-66	miR-17
Manuel <i>et al</i>	2011	Spain	Gastrointestinal Cancer	38	I-IV	Tissue	qRT-PCR	Mean	Given	38	miR-17
Robaina <i>et al</i>	2016	Brazil	Burkitt lymphoma	41	I-IV	Tissue	qRT-PCR	Median	Given	69	miR-17
Xu <i>et al</i>	2014	China	Esophageal Squamous Cell Carcinoma	105	I-IV	Tissue	qRT-PCR	Mean	Given	52	miR-17
Jun <i>et al</i>	2010	Japan	Pancreatic Cancer	80	I-IV	Tissue	qRT-PCR	Median	Given	60	miR-17-5p
Wang <i>et al</i>	2011	China	Gastric Cancer	65	I-IV	Serum	qRT-PCR	Median	Given	36	miR-17-5p
Zheng <i>et al</i>	2013	China	HCC	96	I-IV	Serum	qRT-PCR	Median	Given	NG	miR-17-5p

Revised Table 2 Subgroup analysis.

Subgroup	Number of studies	Heterogeneity		pooled HR (95% CI)	P values
		$I^2$ (95%CI)	P values		
Total	12	38.2% (0% to 68.7%)	0.086	1.42(1.30 to 1.55)	<0.001
Ethnic subtotal					
Non-Asian	2	71.6% (0% to 93.6%)	0.06	1.48(1.21 to 1.81)	<0.001
Asian	10	36.1% (0% to 69.5%)	0.12	1.40(1.27 to 1.55)	<0.001
Disease subtotal					
Digestive system	7	34.8% (0% to 72.4%)	0.163	1.36(1.22 to 1.51)	<0.001
Respiratory system	1	NA	NA	1.28(1.02 to 1.61)	0.036
Blood system	2	0	0.713	2.38(1.56 to 3.63)	<0.001
Glioma	1	NA	NA	1.61(1.19 to 2.18)	0.002
Osteosarcoma	1	NA	NA	1.61(1.19 to 2.18)	<0.001
Detected Sample subtotal					
Tissue	10	46.2% (0% to 74.1%)	0.053	1.45(1.31 to 1.61)	<0.001
Serum	2	0	0.662	1.32(1.10 to 1.57)	0.002

Subgroup	Number of studies	Heterogeneity		P values	pooled HR (95% CI)	P values
		$I^2$	(95%CI)			
Detection of miR-17 subtotal						
miR-17	8	60.1%	(13.2% to 81.7%)	0.057	1.29(1.11 to 1.49)	<0.001
miR-17-5p	4	7.5%	(0% to 43.4%)	0.372	1.50(1.34 to 1.67)	0.001



In addition, there were some errors in the ‘Abstract’ section, under the results subheading, the text should read as:

The results indicated that the increased expression of miR-17 played an unfavourable role in overall survival in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (non-Asian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38) were significant with  $P<0.05$ .

This was incorrectly published as: The results indicated that the increased expression of miR-17 played an unfavourable role in overall survival in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38), detection method (quantitative real-time PCR HR=1.40 and in situ hybridization, HR=2.59) and detection sample (tissue HR=1.45 and serum HR=1.32) were significant with  $P<0.05$ .

The errors in the Results section, should read as:

A total of 1096 patients with various types of cancers were from People’s Republic of China, Japan, Spain and Brazil. Quantitative real-time PCR (qRT-PCR) was used to assess the expression of miR-17 in all studies.

and was incorrectly published as:

A total of 1096 patients with various types of cancers were from People's Republic of China, Japan, Spain and Brazil. Quantitative real-time PCR (qRT-PCR) was used to assess the expression of miR-17 in 12 studies, and one study used the in situ hybridisation (ISH).

The errors in the Discussion section, should read as:

In the subgroup analysis, we found that the potential heterogeneity may have originated from the non-Asian group studies.

and was incorrectly published as:

In the subgroup analysis, we found that the potential heterogeneity may have originated from the Caucasian group in the study conducted by Robaina *et al.* Unlike the commonly used RT-PCR, ISH technique was used to detect miR-17

The errors in the Discussion section, should read as:

However, both studies from Spain and Brazil recruited population of non-Asians decreasing the heterogeneity.

and was incorrectly published as:

However, both studies from Spain and Brazil recruited population of Caucasians decreasing the heterogeneity.

The errors in the Discussion section, should read as:

In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the non-Asian and Asian groups, and the tissue and serum sample groups.

and was incorrectly published as:

In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the Caucasian and Asian groups, the qRT-PCR group and the tissue and serum sample groups.

The errors in the Conclusion section, should read as:

However, further multicentre clinical trials with larger sample size and prospective studies including non-Asian and patients representing other ethnicities are needed to confirm the prognostic value of miR-17 and its subsequent application as a prognostic biomarker in the routine clinical guidance of cancers.

and was incorrectly published as:

However, further multicentre clinical trials with larger sample size and prospective studies including Caucasians and patients representing other ethnicities are needed to confirm the prognostic value of miR-17 and its subsequent application as a prognostic biomarker in the routine clinical guidance of cancers.

Revised table 1A summary table of the meta-analysis

Study	Year	Country	Diseases	Case Number	Stage	Sample	Assay	Cut-off value	HR	Follow-up (months)	Type of miR-17 detection
Chen <i>et al</i>	2012	China	HCC	120	I-IV	Tissue	qRT-PCR	Median	RR	46	miR-17-5p
Qun <i>et al</i>	2013	China	Lung Cancer	221	I-IV	Tissue	qRT-PCR	Median	Given	50	miR-17
Li <i>et al</i>	2014	China	Osteosarcoma	117	I-III	Tissue	qRT-PCR	Median	Given	44	miR-17
Lu <i>et al</i>	2012	China	Glioma	108	I-IV	Tissue	qRT-PCR	Mean	RR	60	miR-17
Xi <i>et al</i>	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	Given	Up to 13 years	miR-17
Yu <i>et al</i>	2012	China	Colon Cancer	48	I-IV	Tissue	qRT-PCR	Median	Given	5-66	miR-17
Manuel <i>et al</i>	2011	Spain	Gastrointestinal Cancer	38	I-IV	Tissue	qRT-PCR	Mean	Given	38	miR-17
Robaina <i>et al</i>	2016	Brazil	Burkitt lymphoma	41	I-IV	Tissue	qRT-PCR	Median	Given	69	miR-17
Xu <i>et al</i>	2014	China	Esophageal Squamous Cell Carcinoma	105	I-IV	Tissue	qRT-PCR	Mean	Given	52	miR-17
Jun <i>et al</i>	2010	Japan	Pancreatic Cancer	80	I-IV	Tissue	qRT-PCR	Median	Given	60	miR-17-5p
Wang <i>et al</i>	2011	China	Gastric Cancer	65	I-IV	Serum	qRT-PCR	Median	Given	36	miR-17-5p
Zheng <i>et al</i>	2013	China	HCC	96	I-IV	Serum	qRT-PCR	Median	Given	NG	miR-17-5p

Subgroup	Number of studies	Heterogeneity		P values	pooled HR (95% CI)	P values
		$I^2$ (95% CI)				
Total	12	38.2% (0% to 68.7%)	%	0.086	1.42 (1.30 to 1.55)	<0.001
Ethnic subtotal						
Non-Asian	2	71.6% (0% to 93.6%)	%	0.06	1.48 (1.21 to 1.81)	<0.001
Asian	10	36.1% (0% to 69.5%)	%	0.12	1.40 (1.27 to 1.55)	<0.001
Disease subtotal						
Digestive system	7	34.8% (0% to 72.4%)	%	0.163	1.36 (1.22 to 1.51)	<0.001
Respiratory system	1	NA		NA	1.28 (1.02 to 1.61)	0.036
Blood system	2	0		0.713	2.38 (1.56 to 3.63)	<0.001
Glioma	1	NA		NA	1.61 (1.19 to 2.18)	0.002
Osteosarcoma	1	NA		NA	1.61 (1.19 to 2.18)	<0.001
Detected Sample subtotal						
Tissue	10	46.2% (0% to 74.1%)	%	0.053	1.45 (1.31 to 1.61)	<0.001
Serum	2	0		0.662	1.32 (1.10 to 1.57)	0.002
Detection of miR-17 subtotal						
miR-17	8	60.1% (13.2% to 81.7%)	%	0.057	1.29 (1.11 to 1.49)	<0.001
miR-17-5p	4	7.5% (0% to 43.4%)	%	0.372	1.50 (1.34 to 1.67)	0.001

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2018;8:e018070corr1. doi:10.1136/bmjopen-2017-018070corr1

